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SUMMARY 
Neural modulation has become a fundamental tool for understanding and treating 
neurological and psychiatric diseases and disorders including Parkinson’s disease and other 
movement disorders, epilepsy, depression, and a growing number of other indications. 
Neural modulation encompasses a range of technologies for stimulating the brain using an 
exogenous signal to modulate neural activity and ultimately, behavior. Electrical and 
magnetic stimulation are used therapeutically and have been used in research applications 
along with optogenetic, magnetic, and ultrasonic stimulation. The stimulation is typically 
defined by a set of parameters that can be adjusted to change the shape of the signal. 
However, delivering the desired therapy or intervention is dependent on using the correct 
stimulation parameters, which can be specific to the neural circuit being modulated, the 
disease being treated, and critically, the individual subject or patient. Researchers and 
medical device manufacturers are continually developing tools with unprecedented 
flexibility for precisely tailoring stimulation parameters for subject-specific interventions. 
As a consequence, this increased flexibility makes it exponentially more difficult to 
identify the optimal stimulation parameters for an individual. Data-driven optimization is 
a well-developed field of engineering that has recently emerged as a solution to the problem 
of selecting stimulation parameters for neural modulation. However, data-driven 
optimization systems must be carefully designed for each specific neural modulation 
problem or they risk failing to find optimal, or even reasonable, stimulation parameters. In 
this dissertation, I demonstrate the importance of and develop a framework for designing 
effective data-driven optimization solutions for specific neural modulation problems. I 
 xvi 
develop this framework in the context of maximizing an electrophysiological biomarker 
using optogenetic stimulation in a rodent model. I then extend the framework to neural 
modulation problems in rodents and humans with relevant design goals: optimization to a 
setpoint, optimization of a state-dependent response, safe optimization, and optimization 
of multiple objectives simultaneously. Through these examples, I demonstrate how this 
framework can improve neural modulation by allowing for more precise subject-specific 






CHAPTER 1. INTRODUCTION 
Neural modulation has recently emerged as a promising therapy for the treatment of 
neurological and psychiatric disorders, and has been a fundamental tool for studying the 
circuitry and physiology of the brain. Neural modulation includes a range of therapies 
including, but not limited to, deep brain stimulation (DBS), transcranial magnetic 
stimulation (TMS) and  optogenetic stimulation. DBS is currently used for the treatment 
of Parkinson’s disease (PD) [1], essential tremor [2] for the treatment of medication 
resistant epilepsy [3], [4], and more recently, for treatment-resistant depression [5], 
obsessive compulsive disorder [6], and Tourette’s syndrome [7]. For research purposes, 
electrical stimulation has been useful for the functional mapping of neural circuits, while 
optogenetics has allowed for the cell type-specific interrogation of the neural circuitry [8]. 
Additionally, non-invasive approaches including TMS [9] and transcranial alternating 
current stimulation (tACS) [10] have been invaluable for studying neurophysiology in 
human subjects. The common feature is that each of these technologies allows for an 
exogenous signal, be it electrical, optical, or magnetic, to be delivered to the brain to drive 
neural activity in a targeted way. The stimulation is typically defined by a set of parameters 
that can be adjusted to change the shape of the signal. However, delivering the desired 
therapy or intervention is dependent on using the correct stimulation parameters, which can 
be specific to the neural circuit being modulated, the disease being treated, and critically, 





1.1 Neural modulation for the treatment of neurological and psychiatric disorders 
1.1.1 Neural modulation for Parkinson’s disease 
PD is a movement disorder characterized by the death of dopaminergic cells in the 
substantia nigra, which can result in motor symptoms including, but not limited to, rigidity, 
akinesia, bradykinesia, and tremor [11]. One of the most effective pharmaceutical therapies 
is levodopa, a dopamine precursor. However, patients can develop side-effects and/or a 
tolerance to the medication that outweighs its therapeutic benefits. When the disease is not 
adequately controlled with medication, DBS is considered.  
In DBS for PD, electrodes with multiple contacts are implanted into one or both of 
the subthalamic nucleus (STN) or the internal segment of the globus pallidus (GPi) – 
specific nuclei of the basal ganglia. The electrode is then connected to a stimulating device 
(internal pulse generator; IPG) implanted in the chest that can deliver an electrical signal, 
referred to as a stimulation setting. In a conventional DBS device (Medtronic Activa, 
Abbott Infinity, Boston Scientific Vercise), the stimulation setting is a charge-balanced, 
biphasic, square wave defined by parameters including the amplitude and widths of each 
pulse, the frequency or rate of the pulses, and contact(s) on the electrode used to deliver 
the stimulation (Figure 1.1). Stimulation can be monopolar where a contact on the 
electrode is the cathode and the IPG is the anode, or bipolar where the anode is another 





Figure 1.1: Placement of the IPG and electrode with example stimulation parameters.  
(Left) Anatomical position of the electrode for STN stimulation connected to the 
subcutaneous IPG in the upper chest area. (Right) A standard stimulating electrode with 
four contacts that form rings around the lead. Each contact can be configured to deliver a 
stimulation waveform defined by a set of parameters. 
After surgery, a clinician adjusts the stimulation parameters to find the setting that 
works best for the individual patient. This is typically approached using a brute-force trial-
and-error approach [12]. Starting with a monopolar review, the neurologist goes through 
each contact and increases the amplitude while observing the patient’s symptoms and side-




of side-effects), then bipolar configurations are evaluated. To streamline this process, 
different guidelines and heuristics have been proposed which have the potential to improve 
the overall therapy [13]. 
 Since DBS was approved by the Federal Drug Administration (FDA) for PD in 
2001, over 160,000 patients have been implanted with DBS devices [14]. Over multiple 
randomized controlled trials, DBS of the STN or the GPi along with medical therapy has 
been shown to control PD motor symptoms better than medication alone [15]. More 
recently, ongoing research has led to the routine use of 8-contact segmented electrodes 
[16], and the development of more experimental closed-loop stimulation systems [17]. 
While these new technologies allow for more precise and effective therapies, there are 
several barriers to fully taking advantage of them. 
The central challenge of DBS programming for PD is the size of the parameter 
space. Along with the device itself, the eight contacts of a segmented electrode can each 
be set as a cathode, an anode, or off. This allows for a total of 39 or 19,683 contact 
configurations. When additional stimulation parameters are included (e.g., amplitude and 
frequency), the size of the potential parameter space grows exponentially larger. This 
challenge is only made greater by the increasingly flexible devices being developed that 
offer more precise therapies, but at the cost of a more complex set of stimulation parameters 
[18]. Further compounding this challenge is the time necessary to measure the effects of a 
single stimulation setting. When adjusting stimulation settings for PD, it can take several 
minutes before the patient responds [19]. With only so much time to program the device, 




Finally, as with any biological system, there is measurement noise. As the patient’s 
underlying state (medication levels, arousal, stress) changes, identical stimulation settings 
can produce slightly different effects. While DBS has been and will likely continue to be 
an effective therapy for PD, current programming approaches may not adequately take 
advantage of the flexibility offered by future generations of DBS devices. 
1.1.2 Neural modulation for epilepsy 
Neural modulation in the form of deep brain and cortical stimulation is also now 
approved for the treatment of epilepsy. There have been two pivotal clinical trials of brain 
stimulation for epilepsy. The stimulation of the anterior nucleus of the thalamus (SANTE) 
trial, and the trial for the responsive neurostimulation (RNS) device developed by 
Neuropace.  
The SANTE trial was a prospective, randomized, double-blinded, parallel group 
clinical study for the treatment of temporal lobe epilepsy (TLE) [3]. Bilateral stimulation 
of the anterior thalamic nuclei resulted in a median seizure reduction of 40.4% after 3 
months of stimulation versus a median seizure reduction of 14.5% in no stimulation 
controls that received only anti-epileptic drugs (AED) [21]. The stimulation parameters 
used were 5 V, 90 µs pulses, 145 Hz, “ON” 1 min and “OFF” 5 mins. During the open 
label period (4 – 13 months) all participants (N = 110) received active stimulation, up to 
7.5 V and 185 Hz . After the open label period, the clinicians were allowed to set any 
parameter provided it did not cause adverse effects. Long-term follow up showed a median 




The other FDA approved brain stimulation device for epilepsy, the RNS, detects 
epileptic activity through electrocorticography (ECoG) and provides brief pulse of 
stimulation in response to the detection of a seizure. The system uses a cortical strip settled 
on the surface of the temporal lobe for ECoG recording and a depth electrode that provides 
stimulation to the hippocampus [4]. A long-term treatment study looking at the efficacy of 
RNS system showed seizure reduction of 75% after 9 years of treatment [4], [22]. Other 
clinical studies have shown the efficacy of hippocampal stimulation in suppressing seizures 
in patients with refractory TLE [23].   
While these studies have shown the promise of using brain stimulation therapy for 
medication resistant epilepsy, none have achieved the ultimate goal of the therapy – seizure 
freedom. Just as in DBS for PD, one of the main challenges is the selection of stimulation 
settings. While less complex 4-contact electrodes are more commonly used, a responsive 
stimulation system like the RNS requires seizure detection parameters to also be selected, 
which creates an additional layer of complexity. Even more so than in DBS for PD, the 
time necessary to measure the effect of a stimulation setting poses a significant barrier. As  
patients do not display symptoms between seizures, a single stimulation setting is evaluated 
based on the number of self-reported seizures between clinic visits. As a result, the 
relationship between stimulation settings and therapeutic efficacy is less clear than in DBS 
for PD and movement disorders. This further motivates the need for approaches to 






1.1.3 Other indications for neural modulation therapy 
Beyond Parkinson’s disease and epilepsy, brain stimulation therapy has found 
traction in the treatment of an even broader list of neurological and psychiatric diseases 
and disorders. DBS has been shown to be effective in other movement disorders including 
essential tremor [2] and dystonia [24], and was FDA approved in 1995 and 2003, 
respectively. More recently, DBS of the subcallosal cingulate – a white matter junction in 
the prefrontal cortex – has been shown to be effective for treatment-resistant depression 
[25]. Additional diseases and disorders for which DBS is being researched include 
obsessive compulsive disorder [6], Tourette’s [7], and post-stroke pain [26]. While a major 
focus of these studies is selecting the correct anatomical target and establishing efficacy, 
there is no reason why these therapies would be exempt from the need for subject-specific 
stimulation settings. 
1.2 Determining stimulation parameters for neural modulation 
1.2.1 Challenges 
Each of the applications of DBS for the treatment of neurological and psychiatric 
disorders shares a common set of challenges. First, as well-established in movement 
disorders, particularly PD, the efficacy of the therapy is directly tied to the stimulation 
setting specific to each subject. Second, unlike more common medical therapies which 
have dosage as the main degree of freedom, DBS has to be programmed with a stimulation 
setting selected from a high-dimensional parameter space that is only getting larger as more 




the size of the parameter space grows exponentially making the problem of selecting the 
optimal stimulation setting even more difficult, if not impossible. This property is known 
as the curse of dimensionality (Figure 1.2) [20]. Not only is it necessary to identify the 
optimal stimulation setting from many options, evaluating the effect of each stimulation 
setting can be time-consuming, particularly in DBS for epilepsy and depression. Finally, 
as with any biological system, the effect of a stimulation setting will have some 
measurement noise, and many clinical and behavioural responses will be subjective. These 
challenges coalesce to make it difficult to efficiently optimize stimulation settings in the 
current generation of DBS devices, and intractable in the next.  
 
Figure 1.2: Curse of dimensionality in deep brain stimulation parameter selection.  
A schematic representation of how the curse of dimensionality makes the size of the 
parameter space increase exponentially as new parameters are added. Each cube represents 
a single stimulation setting in a discretized parameter space. The red cube is the optimal 
stimulation setting within that parameter space, while the grey cubes are all suboptimal. 
Each parameter is a dimension of the parameter space. Five arbitrary values are selected 
for each parameter such that (Left) the 1D parameter space has five possible settings, 
(Center) the 2D parameter space has 25 possible settings, and (Right) the 3D parameter 
space has 125 possible settings. As a percentage of the total parameter space, the optimal 




1.2.2 Current approaches 
There are a number of established approaches for selecting stimulation settings 
from a defined parameter space. While the approaches can vary between application, they 
are most developed in DBS for PD. One of the approaches to DBS programming for PD 
patients uses a brute-force approach to map the parameter space, and then refines 
stimulation according a simple line search algorithm [12]. While typically performed by a 
clinician observing the patient, recent work has automated this approach by using a wrist 
accelerometer to quantify the effect of stimulation settings in real-time [27]. This 
hierarchical brute-force approach has also been recently extended to 8 contact segmented 
electrodes [28]. A more sophisticated approach described in [13] provides a flowchart for 
adjusting the stimulation parameters based on specific symptoms and side-effects observed 
during programming as well as the neural structure being stimulated. 
Beyond the more established approaches, there are multiple lines of research to 
address the problem of selecting stimulation settings from larger and more complex 
parameter spaces. One line of research has been to use biophysical computational models 
of the neural circuitry to evaluate the effect of stimulation settings. For PD, an Izhikevich 
neuron model of the thalamocortical-basal ganglia circuit was used to design stimulation 
settings with complex temporal patterns that were later validated in animal studies and in 
patients [29], [30]. While biophysical models like these and others [31], [32] can be used 
to improve brain stimulation, and are critical to understanding the underlying mechanisms, 
they are often specific to a particular neural circuit, (patho)physiology, and stimulation 




Another approach used a linear time invariant network model to design optimal control 
policies [33]. This is a more flexible approach as it can be fit to individual patients based 
on imaging. While powerful, optimal control approaches may be challenging to implement 
clinically and may face a longer translational pipeline. Finally, one subject-specific 
approach increasingly being used is finite-element modeling of the neural tissue to predict 
the spread and electrical properties of the stimulation [34]. 
1.2.3 Data-driven optimization 
Data-driven optimization through direct interaction is a well-developed field of 
engineering that has recently gained traction as an approach to neural modulation. A data-
driven optimization problem is defined by an objective function (a quantitative measure of 
the response to a stimulation setting; for example, the performance on a behavioral assay 
or the value of an electrophysiological feature), and a search space (the set of all possible 
stimulation settings). Once framed as an optimization problem, there are a range of 
established algorithms that can be applied to quickly and reliably find the stimulation 
setting that maximize the electrophysiological or behavioral objective. Data-driven 
optimization offers several advantages for selecting stimulation settings, including: 
• Standardizing DBS programming across patients  
• Navigating high-dimensional and noisy parameter spaces that are difficult to 
visualize 




• Mathematical guarantee of performance (better stimulation settings) and 
efficiency (in fewer samples). 
Data-driven optimization for brain stimulation is based on three main assumptions. 
First, every subject will have a different response to a given stimulation setting. For 
example, depending on the positioning of the electrode a different amplitude may be 
necessary to stimulate the desired structure in the brain. The second assumption is that the 
response of a given subject – and therefore the best stimulation setting – is a priori 
unknown (Figure 1.3, Left). The goal, therefore, of data-driven optimization is to 
sequentially choose stimulation settings so as to find the one that maximizes the therapeutic 
response in as few samples as possible (Figure 1.3, Right). Finally, the third assumption is 
that the response to stimulation settings is structured in that stimulation settings near each 
other do not have completely random responses. This allows for the effect of tested 
stimulation settings to help estimate or predict the effect of untested stimulation settings 





Figure 1.3: Data-driven optimization for neural modulation.  
Left, each panel represents a generic space of parameters and the corresponding response 
to stimulation. While each subject has an underlying response to stimulation, this is not 
known a priori. Right, to find the optimum of an unknown objective function, a data-driven 
optimization algorithm carefully selects stimulation parameters and measures the response 




Data-driven optimization started making inroads in neuroscience as a technique for 
designing audio-visual and audio stimuli for imaging and psychophysical studies. In [35], 
gradient approximation and Bayesian optimization approaches were used to identify the 
parameterized audio-visual stimuli that selectively activated the temporal and occipital 
cortices as measured with functional magnetic resonance imaging. Similarly, a variation of 
optimization called data-driven active learning was successfully used to efficiently learn 
subject-specific audiograms – a clinical test that measures a patient’s auditory detection 
threshold across a range of frequencies [36]. For neural modulation, data-driven 
optimization has been applied in silico to find the transcranial alternating current (tACS) 
parameters that maximized visual phosphenes across a set of subject derived statistical 
models. In silico, data-driven optimization was used to find the linear control parameters 
that best controlled DBS in a mean-field model of PD, and to find the stimulation 
parameters that maximized a statistical model constructed from patient tremor data. 
However, application of data-driven optimization for neural modulation in vivo has been 
limited. One possible barrier is the need for using the correct data-driven optimization 
algorithm for the specific neural modulation problem, and the consequences of using an 
algorithm less-suited to the task. 
While data-driven optimization is a potentially powerful tool for selecting 
stimulation settings, given the unique requirements of every different neural modulation 
problem, bespoke data-driven optimization algorithms must be carefully designed, or they 
risk failing to find the optimal, or even reasonable, stimulation settings. In this dissertation, 




present a framework for designing effective data-driven optimization algorithms for 
specific neural modulation problems, and demonstrate how it can be applied through 
several use-cases described in the following overview.  
1.3 Overview 
This dissertation is divided into six chapters including the introduction. In Chapter 
2, I develop the foundation of the design framework in an experimentally tractable 
optogenetic stimulation model. In Chapters 3-6, I demonstrate how this framework can be 
extended and applied to several additional neural modulation problems, each with unique 
constraints and challenges. The experimental models used in these chapters are not 
intended to provide a specific therapy or study a particular physiological mechanism, but 
to highlight the breadth of problems that can be solved through data-driven optimization, 
and provide guidelines for how it can be adapted. The following is an extended summary 
of this dissertation highlighting the main contribution and results from each chapter. 
Chapter 2. Framework development with optogenetic stimulation to maximize 
hippocampal gamma power  
I developed this framework in the context of a rodent optogenetic system where 
pulsatile 465 nm light is used to stimulate the medial septum while recording downstream 
activity in the hippocampus. The goal was to design an optimization system to 
automatically search for the stimulation parameters – amplitude, frequency, and pulse 
width – that maximize hippocampal gamma power through direct interaction. The design 




representing the diversity in the response to stimulation. 2) Individual in silico models 
representing each subject in the initial cohort were constructed that estimate how a given 
combination of stimulation parameters affect hippocampal gamma power. 3) These models 
were then incorporated into a simulation platform to rapidly prototype and evaluate the 
performance of different data-driven optimization algorithms. 4) The algorithm with the 
best performance was then deployed for real-time in vivo experiments to search de novo 
for the stimulation pattern that maximizes hippocampal gamma power. While a relatively 
trivial optimization problem, this provided a controlled environment for developing the 
design framework. The goal was to solve a trivial problem (gamma maximization) in a 
non-trivial way with broader implications – designing a bespoke algorithm to find the 
optimum rapidly and efficiently. This work was accepted for publication in the Journal of 
Neural Engineering [37]. This chapter lays the foundation for the more significant 
optimization problems addressed using this design framework in Chapters 3-6. 
Chapter 3. Application of the framework for setpoint objectives 
It may not always be necessary, or even safe to find the stimulation pattern that 
maximally modulates a biomarker. Instead, it may be more appropriate to modulate the 
biomarker to a specific level. To accomplish this, I reframed the optimization problem to 
identify the stimulation parameters that regulate hippocampal gamma to a desired setpoint. 
Then, following the same design framework, I prototype the algorithm with the simulation 
platform, and then deploy it in a second set of real-time in vivo experiments. This work has 





Chapter 4. Application of the framework for state-dependent objectives  
A common concern with neural modulation is that the underlying neural state may 
influence the effect of stimulation. This is the case with optogenetic stimulation under 
isoflurane anesthesia. As isoflurane decreases the conductance of K+ channels, it restricts 
the range of possible stimulation frequencies. Using this as a model system, I extend the 
design framework for prototyping optimization approaches that learn state-dependent 
stimulation policies. This work has been published as a conference paper in the 
Proceedings of the Annual International Conference of the IEEE Engineering in Medicine 
and Biology Society EMBS, 2019. 
Chapter 5. Application of the framework for learnable safety constraints  
Neural modulation is not without risks. Using the wrong stimulation pattern can 
cause uncomfortable side-effects, or even seizures in some subjects. Unfortunately, a 
stimulation pattern that may be optimal for one subject may be unsafe in another. In our 
recent experiments to maximize hippocampal stimulation amplitude, we have found that 
stimulation patterns that are well-tolerated by some subjects can cause memory deficits 
and seizures in others. Therefore, the challenge is to learn the optimal stimulation without 
inducing side-effects in the process. To address this, I adapted the framework to use a 
recent development in Bayesian optimization to incorporate online learning of safety 
constraints. I then used the framework to design an optimization system to safely learn the 
optimal subject-specific stimulation voltage. This work has been published as a conference 




in Medicine and Biology Society EMBS, 2018, and a full journal article is being prepared 
for submission. 
 
Chapter 6. Application of the framework for multiple objectives 
In many applications, there can be multiple, different objectives that need to be 
optimized simultaneously. This is the case in stimulation of the STN for PD. In this therapy, 
it is necessary to use sufficient current to stimulate the STN and produce a therapeutic 
effect. However, over-activation of an adjacent structure, like the internal capsule, can 
cause side-effects such as involuntary muscle spasms. This creates two mutually 
competitive objectives for which there is no one optimal stimulation pattern. Instead, there 
is a set of stimulation patterns that describe the optimal trade-off between these two 
objectives, known as the Pareto set. Using data collected from intra-operative stimulation 
experiments, I used the framework to demonstrate how multi-objective surrogate model 
optimization can be used to efficiently learn subject-specific Pareto set of stimulation 
patterns. This work has been submitted to Journal of Neural Engineering. 
Chapter 7. Conclusions 
 To conclude, the steps of the framework are reviewed by discussing how each was 
implemented across the different neural modulation problems, considerations for applying 
the steps to a new neural modulation problem, and more advanced approaches that may be 
incorporated in future version of this framework. Finally, we consider the engineering, 




CHAPTER 2. FRAMEWORK DEVELOPMENT IN AN 
OPTOGENETIC STIMULATION MODEL 
2.1 Introduction 
We develop this framework in the context of a rodent optogenetic system where 
pulsatile 465nm light is used to stimulate the medial septum while recording downstream 
activity in the hippocampus [38], [39]. The goal is to design a data-driven optimization 
system that looks for the combination of optogenetic stimulation parameters – amplitude, 
frequency, and pulse width – that maximizes the magnitude of gamma power (33-50 Hz) 
measured from the hippocampal local field potential (LFP). While a relatively trivial 
optimization problem, this model provided a controlled environment for developing the 
design framework that captured many of the challenges of neural modulation, including 
the time necessary for each iteration and the sample-to-sample variability in the response 
to stimulation. The goal was to solve a trivial problem (gamma maximization) in a non-
trivial way with broader implications – developing a bespoke algorithm by using a design 
process that can be replicated for other neural modulation problems.  
2.2 Methods 
This framework follows four steps shown in Figure 2.1: 1) We start by 
exhaustively sampling a range of stimulation parameters from an initial cohort of multiple 
subjects. 2) We then use this data to construct an in silico model for each subject that 




power. 3) These models are then incorporated into a simulation platform to evaluate the 
performance of different data-driven optimization algorithms. 4) The algorithm with the 
best performance is then deployed in vivo in new subjects to search for the stimulation 
pattern that maximizes hippocampal gamma power (Figure 2.1C). We then extend this 
algorithm to identify the stimulation parameters that regulate hippocampal gamma to a 
desired setpoint. Following the same framework, we prototype the algorithm with the 
simulation platform, and then deploy it in a second set of real-time in vivo experiments. 
 
Figure 2.1: Conceptual overview of optimization design framework. 
The design process for building a data-driven optimization system. In this conceptual 
overview, we consider a generic space of (stimulation) parameters that have an effect on a 
response of interest. The relationship between the parameters and the response is assumed 
to vary across subjects, have appreciable measurement noise, and be a priori unknown. 
The process of designing and validating an optimization algorithm follows four steps. 1) 
Pilot data is collected by exhaustively sampling stimulation parameters from an initial 
cohort of multiple subjects. 2) This pilot data is then used to construct noisy simulation 
models for each individual subject that can serve as proxies for their in vivo counterpart. 3) 




performance on the proxy models. 4) The data-driven algorithm that performs the best is 
then deployed in vivo in a new subject that was not exhaustively sampled. This is a 
generalizable process that can be applied to design data-driven optimization algorithms for 
other neural modulation contexts.  
 
2.2.1 Surgery, virus injection, implant 
A total of 6 adult male Sprague-Dawley rats (2-3 month old; 250-300 g) from 
Charles River Laboratories (Wilmington, MA, USA) were used for the study. All animals 
were maintained within a 12/12 light/dark cycle vivarium with unlimited access to food 
and water. All procedures were conducted in accordance with Emory University’s Institute 
for Animal Care and Use Committee.   
For each subject, two surgical procedures under anesthesia (1.5-4% inhaled 
isoflurane) were conducted as previously described [40]. First, the viral vector (AAV5-
hSynapsin-Channelrhodopsin2-eYFP) was injected into the medial septum just to the right 
of the midline at a 20° angle to the dorsal-ventral axis (0.40 mm anterior, 2.12 mm lateral 
at the 20° angle, 5.80 mm ventral to pia along the rotated axis). A volume of 1.8 µL 
containing 1012 particles/mL was injected with a rate of 0.35µL/minute using a pulled-glass 
pipette attached to a stereotactically mounted injector (Nanoject, Drummond Scientific 
Co., Broomall, PA, USA). Once the pipette was withdrawn, the scalp was stapled closed, 
and Meloxicam was administered as an analgesic (3-5 mg/kg).   
The second survival surgery was conducted after two weeks, allowing time for 




Tucker Davis Technologies (TDT), Alachua, FL., USA) targeting hippocampal CA3 and 
CA1 was implanted in the right dorsal hippocampus (centered at 3.50 mm posterior and 
2.80mm lateral to bregma). The MEA was lowered ventrally into the brain until single unit 
activity was observed from both the CA1 and CA3 regions. The ferrule was then driven 
into the reopened original injection craniectomy at a 20° angle to the dorsal-ventral axis to 
approximately 5.8mm from the pia along the rotated axis. Correct ferrule depth was 
determined by applying a 17Hz, 10ms, 50 mW/mm2 stimulation for 10s. Finally, the 
craniectomy was sealed with dental acrylic to secure the electrode and the ferrule in place. 
Five 2 mm stainless steel screws were mounted on the skull for electrode’s ground and 
reference wires as well as for the structural support.  
2.2.2 Grid search experiments 
After recovering from the second survival surgery, three subjects underwent several 
grid search experiments. Light was delivered through the implanted fiber optic at all 
combinations of amplitude (10, 30, and 50 mW/mm2), pulse-width (2, 5, and 10 ms) and 
frequency (5, 7, 11, 17, 23, 35, and 42 Hz) for a total of 63 combinations of stimulation 
parameters. Stimulation parameters were applied in a random order for a duration of 20 
seconds, separated by at least one minute. This experiment was repeated three times for 
each of the subjects. Throughout the experiment, LFPs were recorded from the 
hippocampus using an RZ2 BioAmp Processor and a PZ2 pre-amplifier (Tucker Davis 
Technologies (TDT), Alachua, FL., USA). Signals were recorded at a sampling rate of 
24414 Hz, and then down sampled to 2000 Hz to limit the computational load during later 




2.2.3 Neural feature calculation 
For each stimulation sample, the neural features representing hippocampal gamma 
power were calculated for the entire stimulation-on window, and then averaged across the 
16 channels in the hippocampal MEA. Channels with damaged connections were excluded. 
The power spectral density (PSD) was estimated for the entire 20 second recording 
(NFFT=2^16) during stimulation using the multi-taper method from the Chronux toolbox 
(http://chronux.org) and then by summed from 33-50 Hz.  
2.2.4 Ground truth model for simulation experiments 
The stimulation parameters (amplitude, frequency, and pulse-width) and the 
gamma power during stimulation were then fit to a Gaussian process model mapping the 
parameters to the corresponding effect on hippocampal gamma power [41]. 
A Gaussian process is composed of a mean function:   
 µ	 = 	m(𝐱!) (2.1) 
and a covariance function: 
 Σ = 	k(𝐱, 𝐱!) (2.2) 
where 𝐱 is a vector containing the data used to construct the model, and 𝐱! is the sample 




amplitude, pulse-width, and frequency. The output is the gamma power, 𝑌"#$$#, during 
stimulation, drawn from a Gaussian distribution:  
 𝑌"#$$#~	𝒩(µ, Σ) (2.3) 
Ultimately, this model allows for an optimization algorithm to interact with a black-box 
function that, for a given set of stimulation parameters, produces a stochastic response 
drawn from the expectation and variance learned directly from previous experiments. 
2.2.5 Optimization algorithms 
The simulation experiments consisted of evaluating three optimization algorithms 
(Figure 2.2), Each with 12 different configurations. Each configuration was evaluated with 
30 trials for each of the three subject models, for a total of 3*12*30*3=3,240 trials. Each 





Figure 2.2: Overview of the 3 optimization algorithms. 
Left panel: SPSA. Top, Initially, an estimate of the optimal argument (theta, green circle) 
is proposed. Next, the initial theta is simultaneously perturbed in multiple directions to 
define additional search points, (theta 1-n). Middle, These points are then sampled, and the 
gradient from these points is estimated. Bottom, A new value for theta along this gradient 
is selected and the process is repeated. Middle panel: CEM. Top, An initial distribution 
centered within the parameter space with a wide covariance is specified. A fixed number 
of sample points are selected from this distribution. Middle, Each of these sample points 
are then evaluated, and those that best satisfy the objective function are identified as elite 
samples. Bottom, The mean and covariance of the arguments of the elite samples are then 
estimated and used for the distribution in the following iteration. Right panel:  BaO. Top, 
During an initial burn-in phase, sample points are selected from a uniform distribution and 
evaluated. Middle, A Gaussian process model is then fit to the existing data. Based on this 
incomplete model, an acquisition function is then used to propose a candidate sample point 
based on the expectation and uncertainty estimated by the model. Bottom, This proposed 
sample point is then evaluated, the model is updated with the new data, and the process is 
repeated. 
2.2.5.1 SPSA 
SPSA is a variant of gradient descent that uses several samples to calculate an 
approximation of the gradient [42]. An overview of the SPSA algorithm is shown in Figure 
2.2, Left Panel. This allows the algorithm to effectively search objective functions with 
measurement noise. The goal of SPSA is to minimize a loss function 𝐿(𝜃) that is a scalar 
valued measure of performance and 𝜃 is an n-dimensional vector of parameters to be 
optimized. An initial estimate of the optimum 𝜃% is randomly drawn from a uniform 
distribution over the parameter space. Then SPSA generates multiple perturbations of theta 










where ∆% is the standard unit vector for the 𝑘&' dimension of the parameter space, and 𝑐% 
is the step-size of the perturbations. Based on this gradient, the estimation of the optimal 
theta is updated by  
 𝜃5%() = 𝜃5% − 𝑎%𝑔>4𝜃5%9 (2.5) 




 and 𝑐% =
-
(%())"
, where 𝑎, 𝐴, 𝛼, 𝑐, and 𝛾 are configuration 
settings. 
2.2.5.2 CEM 
CEM is a general evolutionary algorithm suited for continuous and combinatorial 
multi-extrema optimization and importance sampling [43]. An overview of the CEM 
algorithm is shown in Figure 2.2, Center Panel. In our implementation, the CEM algorithm 
is initialized by specifying a Gaussian distribution is defined with a mean, 𝜇% ,	centered in 
the parameter space and covariance, 𝜎%, large enough so that it is essentially uniform. M 
candidate points are sampled from this distribution, and their performance ranked. The N 
samples with the greatest performance, Θ.(, are selected, and their mean and covariance are 
used to update the Gaussian distribution according to: 
 𝜇%() = Γ
ΣΘ.(
N +




 𝜎%() = Γ𝑐𝑜𝑣(Θ() + (1 − Γ)𝜎% (2.7) 
where Γ is the learning rate. 
2.2.5.3 BaO 
BaO is a model-based optimization that has been used for optimization of expensive 
cost functions [44]. An overview of the BaO algorithm is shown in Figure 2.2, Right panel. 
As the BaO algorithm samples the objective-function, it iteratively builds a model of the 
underlying data, which is then used to select the area of the parameter space to be 
subsequently sampled.  
In our implementation, the BaO algorithm is initialized by randomly selecting 10 
burn-in samples from a uniform distribution over the parameter space. The burn-in samples 
are sequentially applied while the response is measured. The data is then fit to a Gaussian 
process model by maximizing the log marginal likelihood with regard to the 
hyperparameters. An acquisition function is then applied to the model to determine the next 
sample by considering the trade-off between regions of the parameter spaced expected to 
be near optimal (exploitation) and that have high uncertainty – but the potential to be 
optimal (exploration). The next sample is selected, applied, the model is updated with the 
new data, and the process is repeated. 
We use a Gaussian process with a constant mean function and a third order Matérn 




 𝑘4𝑥/ , 𝑥09 = 𝜎1241 + √3𝑟9 exp4−√3𝑟9 (2.8) 
where 𝑘: covariance, 𝜎12: variance of observation (objective function) and  






	𝑤ℎ𝑒𝑟𝑒	𝜎$2 :	𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒	𝑜𝑓	𝑥$ (2.9) 
The variables 𝜎12 and 𝜎$2  and the mean, 𝜇, are hyperparameters that are adjusted to 
maximize the likelihood.  
In this analysis, we consider three acquisition functions:  
Predicted improvement: 
 𝐻56(x) = Φ\
𝜇(𝑥) − 𝑓(𝑥() − 𝜉
𝜎(𝑥) ^ (2.10) 
Where 𝑥( is the currently estimated optimal input and 𝜉 is a constant hyperparameter to 
facilitate exploration. 
Expected improvement: 
 𝐻76(𝑥) = _
(𝜇(𝑥) − 𝑓(𝑥() − 𝜉)Φ(𝑧) + 𝜎(𝑥)𝜙(𝑧) 𝑖𝑓	𝜎(𝑥) > 0





 𝑧 = d
(𝜇(𝑥) − 𝑓(𝑥() − 𝜉)
𝜎(𝑥) 𝑖𝑓	𝜎
(𝑥) > 0
0 𝑖𝑓	𝜎(𝑥) = 0
 (2.12) 
Upper confidence bound: 
 𝐻89: = 	𝜇(𝑥) + e𝜂𝜅&𝜎(𝑥) (2.13) 
where the sequence 𝜅& was defined as 𝜅& = 2 log k
&#;#
<
l, 𝑡 is the number of samples, and 𝜂 
is a hyperparameter that adjusts how heavily uncertainty is weighed.  
2.2.6 Performance objectives 
2.2.6.1 Distance from the maximum 
The distance from the maximum was calculated using the expectation of the 
ground-truth model from the optimal stimulation parameters proposed by the optimization 
algorithm. In other words, whenever an optimization algorithm reaches an update (SPSA: 
3 samples, BaO: 1 sample, CEM: variable), the current estimate of the parameters that 
maximize the objective function (x+) is used as the input to the ground-truth model to 
produce y+. The distance from the optimum is then calculated as the output of the true 




 𝐷𝑀 = 𝑦∗ − 𝑦( (2.14) 
2.2.6.2 Convergence rate 
To measure the overall convergence rate of an optimization 
algorithm/configuration, the distance from maximum as a function of samples was fit to an 
exponential function of the form 
 𝐷𝑀 = 𝑎𝑒>& (2.15) 
Where DM is the distance from the max as described previously, and x is the number of 
samples collected thus far. This was done for each optimization trial, and the coefficient b 
was considered the convergence rate. A more negative coefficient b indicates that the 
algorithm converged to a proposed optimum more rapidly than one with a less negative 
coefficient b. It should be noted that the convergence rate and the final distance from 
maximum represent different aspects of the optimization performance. For example, it is 
possible for an algorithm to rapidly converge, but to a parameter set that is far from the 
maximum. 
2.2.7 Simulation experiments 
In the first application of the framework, the simulation models (Chapter 2, Section 
2.5) were used to evaluated the performance and behavior of the data-driven optimization 




simulation models for each of 3 subjects (R1-R3) were applied to each of the 3 
representative algorithms with 12 different configurations.  Each configuration of each 
algorithm was evaluated for 30 trials of 100 samples per trial. In between each trial the 
system was reset and the optimization algorithm was started from scratch. 
2.2.8 In vivo optimization 
Two animals (R4 and R5), used to validate the optimization platform were prepared 
using the same procedure as for those used to collect exploratory data. After at least two 
weeks for recovery, subjects underwent the optimization experiments. The experiments 
were conducted in a single session consisting of two phases: optimization and validation 
separated by 15 minutes. During the learning phase, the optimization algorithm searched 
for the stimulation parameters that maximize the objective function, while the testing phase 
verifies that the learned parameters were reproducible and not the product of an unrelated 
neural state change (sleep/wake), or the consequence of repeated stimulation. The 
optimization and test phases were performed once per day, except for one subject that 
underwent two experiments within a single day. Each subject underwent four sets of 
optimization/validation. 
 
2.2.8.1 Optimization phase 
In the optimization phase, each subject was connected to a light emitting diode 




(Tucker Davis Technologies, Alachua FL). A custom software application (MATLAB 
2014b) was used to stream the data from the DAQ and control the output of the LED. The 
software application was then configured to run the best performing optimization algorithm 
based on the findings from the simulation experiments. Each sample consisted of 20s of 
stimulation separated by 80s. Ten initial samples drawn from a uniform random 
distribution were used for the burn-in period, followed by 20 samples guided by the 
algorithm. For each stimulation, gamma power was calculated as described previously.  
2.2.8.2 Validation phase 
During the validation phase, 30 stimulations were delivered – randomized between 
sham stimulation, the stimulation parameters supposed to induce the highest hippocampal 
gamma power (estimated optimal), and the one supposed to induce the lowest gamma 
power (estimated worst). Each stimulation was applied as in the optimization phase (20 
seconds of stimulation followed by 80 seconds of washout between samples). 
2.2.9 Analysis and statistics 
In the simulation experiments, final error and convergence rates were compared 
within subject using ANOVA and followed by Tukey post-hoc testing (MATLAB 2020a). 
The variability between subjects was not a focus of this study so these results were not 
explored quantitatively. The testing phase data was analyzed using ANOVA followed by 
Tukey-Kramer post-hoc testing (MATLAB 2020a) to compare the hippocampal gamma 





2.3.1 Ground-truth models map from medial septum optogenetic stimulation parameters 
to hippocampal gamma power 
Hippocampal recordings during optogenetic stimulation of the medial septum were 
collected from three subjects as part of a previous study [38], [39]. (Figure 2.3A) In this 
study, a grid of stimulation parameters with 63 combinations of amplitude, frequency, and 
pulse width, was specified. From this grid, 1267 samples were collected, each sample 
consisting of the stimulation pattern applied and the measured hippocampal gamma power 
(Figure 2.3B,C). As previously observed in [39], the pulsatile stimulation produces a sharp 
peak in the spectral power at the stimulation frequency along with harmonics at multiples 
of that stimulation frequency (Figure 2.3B). 
Using this data set, subject-specific models mapping the stimulation parameters 
(amplitude, frequency, and pulse width) to the hippocampal gamma power were 
constructed by fitting the data to a Gaussian process regression model [45]. The expectation 
of the Gaussian process models corresponding to each subject are shown in Figure 2.3D. 
In each of these representations, the three-dimensional model has been projected into two 
dimensions, omitting pulse width as the data showed it had only a slight effect on the 
hippocampal gamma power during stimulation (Chapter 2, Section 5.1). Plotting the 
expectation of each of the subject-specific models highlights the slight variation between 
the subjects. The primary distinguishing feature is the presence or absence of a subtle local 




maximum can be seen in subject R2, while R3 has an inflection point (i.e., is flat) at 17 Hz, 
but only has a single global maximum. R1 only has the single maximum at 42Hz/50 
mW/mm2. Looking at the measured data (black dots), it is clear that there is a degree of 
uncertainty in the response to identical stimulation parameters. Overall, the effect of 
stimulation on hippocampal gamma power is relatively consistent between subjects, which 
will allow us to assess the performance of an optimization algorithm on new animals 
without performing an exhaustive grid search. Models for control subjects transfected with 
a viral construct missing the opsin necessary for the cells to respond to optogenetic 
stimulation are shown in in Chapter 2, Section 5.2. 
 
Figure 2.3: Construction of the of ground-truth objective function models. 
Objective function models generated from previously collected data. A) Local field 
potentials from three representative samples in subject R1, scale bars for 1s and 0.1 mV. 




Vertical black lines indicate the gamma frequency range (33-50 Hz). C) Focus on gamma 
frequency range. Shaded area indicates standard deviation. D) The surface shows the 
expected response to stimulation at a given frequency and amplitude. Each dot is an actual 
measurement from a single sample. Color gradient is provided solely for contrast and to 
improve visualization. 
2.3.2 Platform for prototyping data-driven optimization 
The models mapping medial septum stimulation parameters to hippocampal 
gamma power were used to construct a simulation platform for prototyping optimization 
algorithms. The prototyping platform was used to evaluate the three representative data-
driven optimization algorithms, each with 12 different configuration settings that govern 
its behavior (e.g., learning rate, parameter space exploration) selected to highlight the 
breadth of behaviors possible with the algorithms, and based on the experimental 
constraints. Each configuration of each algorithm was evaluated for 30 trials of 100 
samples per trial. See Methods for a detailed overview of the optimization algorithms and 
their configurations.  
Figures 2.4A-C show the final performance of the optimization algorithms at each 
configuration for subject R1. Results for other subjects are detailed in Chapter 2. Section 
5.3, but the trends were similar. Overall, for the majority of hyperparameter settings, BaO 
had the lowest final error. Comparing these final results, there was a difference in the 
sensitivity of the optimization algorithms to their configurations settings. SPSA was the 
most sensitive, with CEM showing some sensitivity, and BaO being sensitive to changes 
in configuration primarily when using the predicted improvement (PI) acquisition function 
– the strategy for selecting the next stimulation pattern. Notably, when configured to reduce 




comparable to BaO with the PI acquisition function. (See Methods for a description of the 
algorithm configurations.) 
Figures 2.4D-F show single-trial representative traces from each of the algorithms 
for the hyperparameters that produced the lowest overall final error. These traces 
demonstrate the difference in the search strategies that characterize each algorithm class. 
The SPSA algorithm (Figure 2.4D) shows rapid jumps in the estimate of the optimal 
parameters (solid green line) as new local maxima are found, while the parameters sampled 
(dotted green line) start with a high variance that decreases as the algorithm reduces the 
aggressiveness of the exploration with each subsequent sample. For CEM (Figure 2.4E), 
the estimate of the optimal parameters (solid orange line) evolves much more smoothly as 
each subsequent generation overlaps with the previous, while the variance of the search 
points (dotted orange line) also decreases as the variance of the elite samples is always 
lower than that of the overall population. Finally, for BaO (Figure 2.4F), the estimate of 
the optimal parameters (solid purple line) is rapidly identified for the amplitude and 
frequency, and more slowly for pulse-width. In contrast to SPSA and CEM, the variance 
of the search points (dotted purple line) increases later into the optimization process. This 
is due to the UCB acquisition function that increases the weight of the exploration term 
logarithmically with the number of samples. 
In Figure 2.4G the overall convergence behavior across trials is shown for the 
representative optimizers with the lowest error. In the first 30 samples of the optimization 
process, BaO has the lowest error, followed by CEM then SPSA. After the 45th sample 




specific models is shown in Figure 2.4H. In all subjects, BaO has the lowest final error. In 
subjects R2 and R3, CEM performs nearly as well as BaO, however, in R1 CEM performs 
worse than both SPSA and BaO. Figure 2.4I compares the convergence rate of each 
representative optimization algorithm across subjects and shows that BaO converges most 
rapidly, while SPSA and CEM are significantly slower. 
 
 




(A-C) The final error statistics for running the optimization algorithms under different 
configurations on a single subject. Boxplots show the quartiles and the ‘x’ indicates the 
mean error.  The labels on the x-axis ticks describe the specific configuration used for each 
optimization experiment. The highlighted results indicate that for a given optimization 
class, that specific configuration had the lowest final error for at least one of the subjects. 
(D-F) Each subplot shows a trace for a single representative trial for a single subject using 
the best configuration for that subject. The colored solid line indicates the stimulation 
parameters the optimization algorithm estimated to be optimal, while the colored dotted 
line shows the actual stimulation parameters sampled. Black dashed line is the ground-truth 
optimal stimulation parameter known from the model. (G) The overall trajectory of the 
final error for the class-representative configuration with the lowest error for that subject. 
Each trace indicates the median and quartiles across all trials at that sample number. 
Markers indicate the samples at which the optimal stimulation parameters could be 
estimated as it can vary between optimization algorithms. (H) The mean final error across 
all trials of the algorithm/configuration with the lowest final error for each of the subjects. 
Error bars show the standard error across all trials. *p<0.01, **p<1x10-4, ***p<1x10-7. (I) 
Same as 2.4H for convergence rate. *p<0.05, **p<0.01, ***p<1x10-5. 
Based on these results, we can infer that the BaO algorithm using the UCB 
acquisition function with configuration setting nu=0.4, henceforth referred to as UCB(0.4), 
is best suited to the task of identifying optogenetic medial septum stimulation parameters 
that maximize hippocampal gamma power. While these findings support the potential 
utility of data-driven optimization for neural modulation, they are limited by the in silico 
nature of the experiments. We therefore sought next to validate them in vivo. 
2.3.3 Validation of Bayesian optimization in vivo 
Two subjects (R4 and R5), not included in the development of the prototyping 
platform, underwent optimization to maximize hippocampal gamma power using the 
UCB(0.4) algorithm in a prospective testing phase three times over the course of two 
weeks. Conditions of the experiment were analogous to those used for prototyping in silico. 





2.3.3.1 Optimization phase 
Figure 2.5 shows the trajectory of the algorithm during the optimization phase in 
vivo. At each sample, the estimated optimal stimulation parameters and the predicted 
hippocampal gamma are shown with solid lines. The actual stimulation parameters 
sampled are shown with dotted lines. In all trials, the algorithm rapidly converged on 
expected amplitude and frequency parameters within 10-15 samples. In contrast, the 
algorithm’s estimate of the pulse width did not readily converge in all trials, and the final 
estimate of the optimal pulse widths was more varied (Figure 2.5A and C). The final 
estimated amplitude and frequency parameters strongly agree with both the modeled data 
and the optimization results. Moreover, the ‘lack’ of convergence and wide range of final 
values for pulse width also agrees with our previous results, and confirms pulse width’s 
weak influence on hippocampal gamma above 2 ms. Figure 2.5D shows the spectrogram 
of a representative trial with subject R4. In the beginning of the optimization, the first 10 
samples are randomly selected in what is referred to as the ‘burn-in’. This can be seen from 
the variability in the amplified frequency bands in the spectrogram, both in the frequency 
range of the band and in its brightness as different combinations of amplitude and 
frequency are applied. In the six samples following this initial burn-in period, the amplified 
frequency bands become focused within the 30-42 Hz range and display more consistent 
brightness as the algorithm begins to converge on the optimal stimulation parameters. 
Finally, through the rest of the learning phase the amplified frequency bands are nearly 
uniform in both frequency range and brightness, as nearly identical stimulation parameters 




subjects, there is considerable consistency in the behavior and performance of the 
optimization algorithm in this task. Moreover, at the end of each trial the estimated optimal 
stimulation parameters for amplitude and frequency fall within a very narrow range (45-50 
I, and 35-42 Hz) corresponding to the back corner of the parameter space, as represented 
in Figure 2.3D. While the estimated optimal stimulation parameters are consistent between 
trials and subjects, the effect of the stimulation on gamma power is less so, as the magnitude 
of the response to stimulation can vary between subjects and implanted hardware. This is 
highlighted in Figure 2.5B, where damage to the recording electrode decreased the overall 
amplitude of the signal. So, while the estimated optimal stimulation parameters are the 






Figure 2.5: Trajectory of maximization of hippocampal gamma power in vivo. 
(A) Stimulation parameter search trajectory and the effect of stimulation on hippocampal 
gamma power for three trials in subject R4. Solid lines indicate the optimization 
algorithm’s estimate of the optimal stimulation parameters and their predicted effect, while 
the dotted line shows the actual stimulation parameters sampled and the actual 
hippocampal gamma power induced. Grey box indicates the 10 samples that were collected 
as part of the burn-in period for BaO. (B) Re-scaled effect of stimulation on hippocampal 
gamma power to show two trials with reduced signal amplitude for subject R4. (C) 
Corresponding stimulation parameter search trajectory and effect on hippocampal gamma 
power for subject R5. (D) Spectrogram of the hippocampal LFP from a representative 
optimization trial in subject R5. One second non-overlapping window, with post 




2.3.3.2 Validation phase 
After the optimization phase and a short delay to allow for the washout of any 
potential accumulated effects, each subject underwent a post-optimization validation-
phase. Overall, the estimated optimal parameters produced a hippocampal gamma power 
2-2.5 times that during sham stimulation (Figure 2.6A). The stimulation parameters 
estimated to have the worst performance on the objective function (either no effect or a 
decrease), did not induce a statistically significant increase compared to sham stimulation 
(two-sample t-test, p-value > 0.05). Figure 2.6C shows the mean wideband power spectral 
density (PSD) for the three conditions from a representative trial. For the estimated optimal 
stimulation parameters there is a large peak at 36.7 Hz corresponding to the applied 
stimulation frequency, along with its harmonic at 73.1 Hz. For the estimated worst 
stimulation parameters, there are harmonics at approximately every 15 Hz. As described 
in our previous work, these harmonics are expected at multiples of the stimulation 
parameters [40]. No such peaks or harmonics are seen for the PSD under sham stimulation. 
Focusing on the gamma range in Figure 2.6D there is a large peak for the estimated optimal 






Figure 2.6: Validation phase for stimulation parameters to maximize hippocampal 
gamma power.  
(A) Gamma power for each randomized trial of the three conditions: sham, estimated 
optimal, and estimated worst stimulation pattern during the validation phase. Lines connect 
the mean hippocampal gamma power across the 10 samples for each trial/subject. (B) LFP 
from under the three conditions from a single channel during a representative sample. 
Dotted black line shows the period of time when stimulation was applied, scale bars for 1s 
and 0.1mV. (C) Average power spectrum for each of the three conditions from a 
representative testing phase. (D) Power spectrum focused on the gamma frequency range. 






2.4.1 Optimization framework recap 
Selecting neural modulation parameters is a challenge that spans much of 
neuroscience, neurology, neurosurgery, even psychiatry. Evaluating the effects of any 
neurological intervention is time and resource intensive, all the more so with neural 
modulation therapies where the high dimensionality of stimulation parameters makes the 
problem of finding the optimal choice even more difficult, if not intractable. The 
optimization framework presented here offers a principled approach to address this 
problem. Starting with exploratory data, users can construct ground-truth models that allow 
for optimization algorithms to be rapidly and repeatedly prototyped and evaluated using a 
simulated system with the necessary black-box characteristics. As we have shown, these 
algorithms can be directly applied in real-time to learn subject-specific optimal stimulation 
parameters.  
2.4.2 Developing a platform for prototyping data-driven optimization algorithms 
The first step in implementing this framework is the construction of the ground-
truth models. While any optimization algorithm can be deployed in vivo without being 
evaluated on ground-truth models, this greatly increases the risk of an unsuccessful 
optimization and provides little to no recourse for interpreting the failure. Here, our data 
was already collected using a pre-specified grid. However, a random search or importance 
based sampling could be potentially used to greater effect. Moreover, the structure used for 
modeling the data is not limited to a Gaussian process. Alternative model structures that 




architectures that directly model noise and uncertainty, [47] and biophysical models. 
Ultimately, selecting the model structure and fitting approach should be guided by the 
optimization problem in question. 
2.4.3 Designing an optimization system for neural modulation 
By using the simulation models for prototyping, the framework predicted that 
among those tested, the UCB(0.4) algorithm would perform best at maximizing 
hippocampal gamma power. While the predicted performance of UCB(0.4) was born out 
the in vivo optimization and validation experiments, this does not fully highlight the 
predictive value of the framework. When prototyping algorithms, a version of the UCB 
acquisition function with decreased exploration, UCB(0.01), performed worse than 
UCB(0.4) as it would prematurely converge to a suboptimal set of stimulation parameters. 
This behavior was correctly predicted by the framework in a small set of control 
experiments (Chapter 2, Section 5.4), demonstrating that it could detect the nuanced 
differences between these two algorithms.  
There are several factors that can prevent successful optimization. In particular, 
optimization is only possible if the selected parameter space can have the desired effect on 
the objective function. For example, all stimulation settings within this parameter space 
caused an increase in hippocampal gamma power, such that it would be futile to search for 
stimulation settings to decrease hippocampal gamma. Another critical factor is the correct 
engagement with the neural tissue and accurate measurement of the objective. One example 




After the first trial, the recording electrode was damaged which resulted in an overall lower 
signal amplitude, decreasing hippocampal gamma under baseline and stimulation 
conditions. Had the electrode suffered further damage or been incorrectly positioned during 
surgery, there would be no signal to optimize. The potential for changes in the underlying 
biophysical system (electrodes, behavioral state, etc.) to influence the effect of stimulation 
parameters on the objective function highlights the importance of our ongoing work to 
develop optimization approaches that can adapt to changing situations [48]. In sum, while 
data-driven optimization can be a powerful tool, it is only as effective as the combination 
of the parameter space, the objective function, and engagement with the neural tissue. 
An important decision in the development of this framework was the experimental 
model. The medial septum optogenetic stimulation model offered several key advantages. 
First, the relationship between the pulsatile stimulation parameters and hippocampal 
activity was characterized in our previous work. In [39], we showed that pulsatile 
stimulation at a given frequency induces evoked potentials in hippocampus at that 
frequency. In the frequency domain, this creates a sharp peak at the stimulation frequency 
and harmonics at multiples of that frequency. Then, as shown in [38], we can reasonably 
anticipate the stimulation parameters that will maximize a spectral power feature (i.e. 
gamma). Combined with the consistency between subjects, this allowed us to 
independently verify the results of the search algorithm when applied to an unknown 
subject. The lack of subject-to-subject variability does differ from the clinical scenario 
where each patient has a different optimal stimulation setting. However, through the 




the designed algorithm, UCB(0.4), could generalize across multiple different objective 
functions.  
While the experimental model was well-suited to the development of this 
framework, it also limits some of the conclusions that can be drawn from this study. Based 
on the findings in [38] we chose to use gamma power as the neural feature to maximize. 
However, while medial septum optogenetic stimulation acts via biological conduction 
along the septohippocampal circuit, it is not necessarily physiological. In other words, the 
increase in gamma power from the optimal stimulation is not equivalent to naturally 
elevated gamma during certain tasks [49]. With these limitations in mind, this experimental 
model can serve as a valuable toy problem for prototyping novel neural modulation 
algorithms, just as the MNIST dataset is for machine vision [50]. Another limitation of this 
study was the parameter space used. While we restricted ourselves to a fairly narrow 
frequency band to ensure proper functioning of our opsin [51], future work will explore 
how data-driven optimization behaves with larger and more complex parameter spaces and 
objective functions in this model. Finally, the specific stimulation protocol differed 
between the initial data collection experiments (20 seconds of stimulation followed by 60 
seconds of washout) and the real-time optimization experiments (5 seconds of stimulation 
followed by 25 seconds of washout). While a potential disconnect, the UCB(0.4) algorithm 
designed based on the longer stimulation protocol performed similarly and identified 
equivalent optimal stimulation settings in the real-time experiments using the shorter 




could warrant a re-design of the optimization algorithm by repeating the steps of the 
framework.  
The purpose of this demonstration is not to provide a solution, e.g., UCB(0.4), to a 
narrowly defined problem – modulating hippocampal gamma power with optogenetic 
stimulation of the medial septum – but  to instead provide a roadmap to guide solutions for 
a broader problem that permeates all of neural modulation. While the implementation of 
the framework presented here centered around optogenetic stimulation, which does not 
have an immediate pathway to clinical translation, there is no reason this framework cannot 
be extended to clinical therapies. Several extensions of the standard optimization 
algorithms may find specific application in the clinical domain. These include: multi-
objective optimization where multiple objectives are mutually competitive and need to be 
addressed simultaneously [52]; safe optimization where regions of the parameter space 
may be unsafe but the location of these regions is unknown a priori [53]; and preferential 
optimization where the objective function is more subjective [54]. Finally, there is state-
dependent optimization, where the algorithm learns a stimulation policy that depends on 
the current state of the neural system. Taken to its logical conclusion and combined with 
approaches from control theory, state-dependent optimization is a direct pathway to the 
application of optimal control techniques to neural modulation. Ultimately, using this 
framework as a starting point to guide the use of exploratory data and simulation models, 
data-driven optimization approaches are well-poised to improve the process of tailoring 




In the next several chapters, I will show how this framework can be extended to 
different applications of neural modulation, each with unique properties and constraints. 
2.5 Supplement 
2.5.1 Pulse width has a slight effect on induced hippocampal gamma power 
Figure 2.7 shows the effect of pulse width on gamma power for subject R1. Three 
independent 2 dimensional models were constructed using the stimulation parameters and 
measured gamma power for each of the pulse widths (2, 5, 10ms) tested in the grid search 
experiments. This pattern was observed in the other subjects (R1 and R2, data not shown) 
as well. 
 
Figure 2.7: Modeled data at different pulse width cross-sections. 
Surfaces show the expected gamma power a model fit to the data for specific pulse widths. 
Each dot indicates the stimulation parameters and measured gamma power. The color scale 
is for visualizing contrast within models. 
2.5.2 Control animals without ChR2 opsin demonstrate lack of photoelectric effect  
A major consideration in any neural modulation experiment is differentiating 




when optimizing stimulation based on an electrophysiological objective function. If the 
optimization algorithm is detecting the artifact instead of the real signal, it risks optimizing 
the artifact instead of the desired electrophysiological signal. 
To control for this, two animals were transfected with a virus containing just the 
hSyn promotor and the eYFP fluroescent indicator. Subjects underwent the same surgical 
procedure and grid search experiments as described in the methods. Similarly, for each 
stimulation the gamma power was measured and used to create a simulation model. 
Figure 2.8 shows the expectation estimated from the models created for the two 
control subjects, and subject R1. By plotting the two models on the same scale, it can be 
readily observed, from the perspective of the gamma simulation model, there is no response 
to stimulation in the control subjects. This is evident in the different amplitudes of the 
models, and the inconsistent shape of the control models compared to the three models 
with the opsin (Figure 2.2). This supports the lack of stimulation artifact in the objective 
function measured from the hippocampus. 
 




Each surface is the estimated expectation interpolated across the amplitude-frequency input 
space. The color scale is for visualizing contrast within models. 
2.5.3 Simulation results for subjects R2 and R3 
Simulation experiments were completed for each of the models created using data 
from each of the three subjects. Figure 2.9 shows the final error of the simulation results 
from subjects R2 and R3. 
 
 
Figure 2.9: The final error statistics for running the optimization algorithms under 
different configurations on subject models R2 and R3. 
Boxplots show the quartiles and the ‘x’ indicates the mean error. The labels on the x-axis 
ticks describe the specific configuration used for each optimization experiment. The 
highlighted results indicate that for a given optimization class, that specific configuration 




2.5.4 Framework predicts optimization performance for different 
algorithms/configurations 
In the main body of this chapter, we demonstrated using this framework to design 
in silico and deploy in vivo an optimization algorithm for finding the medial septum 
optogenetic stimulation parameters that maximize hippocampal gamma power. To 
reinforce this, we further validate that the results of the in silico experiments could 
accurately predict the performance of a given optimization algorithm when deployed in 
vivo.  
The BaO UCB acquisition function has a single configuration parameter 𝜂, which 
controls the relative exploration of the algorithm. When 𝜂 is high, the algorithm will weigh 
uncertainty more heavily than the expected output of the objective function. When 𝜂 is 
low, the acquisition function will preferentially select stimulation parameters expected to 
produce high gamma power with little uncertainty. As a consequence, the algorithm will 
not explore the parameter space, but will instead prematurely converge to the best 
stimulation parameter observed during the burn-in phase. Therefore, we would expect the 
in silico experiments to show faster convergence and higher overall error with the 
UCB(0.01) algorithm than with UCB(0.4), which should then be recapitulated when 
deployed in vivo.  
In this supplementary experiment (2.5.4), we directly compare the performance of 
UCB(0.01) and UCB(0.4) in silico and in vivo. The simulation experiments were conducted 




samples, as opposed to 100 samples. The data model for subject R1 was used. The in vivo 
optimization and validation phases were performed using subjects R4 and R5 as described 
in the methods for an additional trial using the UCB(0.01) algorithm. 
Figure 2.10 compares the in silico results of using the UCB(0.01) algorithm 
compared to UCB(0.4). Figure 2.10A shows the error trajectory averaged by sample for 
the two algorithms. While both start at the same mean error of 0.4, the error for the 
UCB(0.4) algorithm decreases much more rapidly and persistently. In contrast, the 
UCB(0.01) algorithm error levels off faster and after 30 samples has a much higher final 
error. Figure 2.10B compares the overall distribution of the final error for the two 
algorithms. It can be seen that, not only does UCB(0.4) have an overall lower error, the 
variance of the distribution is also smaller. In contrast, the range of final errors for 
UCB(0.01) extends all the way to ~0.6, while the worst outlier for UCB(0.4) is just above 
0.3. Overall, these findings show that, in simulation, the framework predicts that 





Figure 2.10: In silico performance of UCB(0.4) vs. UCB(0.1).  
(A) Per sample error of the optimal stimulation parameter estimated by the algorithms. 
Center line and shaded regions indicates the per sample mean and standard error, 
respectively, across 30 trials. (B) Boxplot showing the range and quartiles of the final error. 
Outliers marked with +, and X indicates mean including outliers. 
 
Figure 2.11A shows the in vivo optimization phase for subject R4. In the amplitude 
trajectory, we can clearly see that UCB(0.01) has rapidly converged to a lower amplitude, 
20 mW/mm2, compared to the assumed optimum of 45-50 mW/mm2. The lack of 
exploration by UCB(0.01) is also evidenced by the consistency in the sampled amplitude 
compared with the estimated optimal. While UCB(0.01) found the expected optimal 
frequency, and pulse width does not have a profound effect on the induced gamma power, 




gamma power. The poor performance of the stimulation parameters estimated by 
UCB(0.01) were verified during the validation phase (Figure 2.11B).  
 
 
Figure 2.11: Performance of UCB(0.01) compared to UCB(0.4) in vivo. 
(A) Stimulation parameter trajectories of the two algorithms during the optimization phase. 
The solid lines indicate the per sample optimal value of the stimulation parameters 
estimated by the algorithm, while the dotted lines indicate the actual stimulation parameters 
sampled. The purple lines show the optimization results using the UCB(0.4) algorithm as 
previously shown in Figure 2.4, while the pink lines are the results using UCB(0.01). The 
gray box indicates the 10 burn-in samples at the beginning of each optimization trial. (B) 
The induced hippocampal gamma using the estimated optimal stimulation parameters. Box 
plots show the range and quartiles for the three trials using UCB(0.4) (purple) and 






2.5.5 Performance of UCB(0.4) on subject data and benchmark models 
While the main focus of the framework is on designing optimization algorithms for 
specific neural modulation problems, it is also important to characterize the limitations of 
the resulting optimization algorithm. To demonstrate this, we evaluated the performance 
of the UCB(0.4) optimization algorithm on three representative benchmark objectives 
along with the model derived from subject R1.  
The three objectives used were, a quadratic/sphere objective: 




The Rastrigin objective: 
 𝑓(𝑥) = R10 + 𝑥32 − 10 ∗ cos	(2𝜋
?
34)
∗ 𝑥3) (2.17) 
And the Easom objective: 





$&'  (2.18) 
For each objective, we used 1, 2, and 3-dimensional (D) variations and compared with 




and the frequency, amplitude, and pulse width (3D). For each objective/model, we adjusted 
the measurement noise to sweep nine different values of the contrast-to-noise ratio (CNR) 
[0.1, 0.5, 1, 1.5, 2, 3, 4, 5]. The UCB(0.4) algorithm was evaluated on each model/CNR 
combination for 30 trials of 100 samples each, as described in the methods. 
 Figure 2.12A shows the three 1D benchmark objectives and model for R1. From 
the 1D variations of these objectives, the difference in the difficulty can be seen. The 
simplest, sphere/quadratic function, has a single maximum and is overall relatively simple. 
Slightly more difficult is the model from subject R1, which has two local extrema, one of 
which is much higher than the other. The third objective, the Rastrigin function, has many 
local extrema over its domain, of which many are similar, but only one is the global 
maximum. Finally, the Easom function is relatively flat across much of its domain, with a 
sharp spike to create the global maximum. In Figure 2.12B, the final error and convergence 
rate for UCB(0.4) is shown for each of these functions as the CNR is adjusted. Across CNR 
values, the sphere/quadratic objective and model for subject R1 perform similarly, although 
at lower CNR levels, they have relatively high errors, but still show some optimization 
after 100 samples. The UCB(0.4) performs slightly worse with the Rastrigin function at 
lower CNR levels, but more comparably to the sphere and R1-frequency models as the 
CNR increases. For the Easom model, the algorithm performs poorly and variably at low 
CNRs. The performance of the algorithm increases with CNR, but still worse than with the 
other three.  





Figure 2.12: Performance of UCB(0.4) on 1 dimensional benchmark functions. 
(A) 1D variations of the 3 benchmark objective and the frequency model for subject R1. 
(B) The final error and convergence rate of the UCB(0.4) algorithm as the CNR is 





Figure 2.13A shows the 2-dimensional counterparts for each of the three 
benchmark objectives and the frequency/amplitude model for subject R1. While mostly 
similar to the 1D versions, the Easom model becomes even more difficult as the main 
region of variability covers a much smaller proportion of the parameter space. This 
increased challenge is reflected in Figure 2.13B, where the UCB(0.4) algorithm 
completely fails to find the optimum for the Easom 2D objective at low CNR values, and 
only occasionally finds the optimum at higher CNR levels. The other two benchmark 
objectives and the subject model perform similarly as in the 1D cases, albeit with more 
stratification in the performance at lower CNRs where the algorithm performs best on the 










(A) 2D variations of the 3 benchmark objective and the frequency model for subject R1. 
(B) The final error and convergence coefficient of the UCB(0.4) algorithm as the CNR is 
increased. Vertical bars indicate the standard error across 30 trials. 
 
While it is difficult to visualize the 3D version of each of the benchmark objectives, 
Figure 2.14A shows that the overall trend is preserved. The Easom models becomes 
completely unoptimizable within 100 samples at any CNR, while the others become more 
tractable with increasing CNR. As in the 2D case, the algorithm performs comparable on 
the sphere objective and model for subject R1, and slightly worse for the Rastrigin model. 
 
Figure 2.14: Performance of UCB(0.4) on 3 dimensional benchmark functions.  
(A) The final error and convergence rate of the UCB(0.4) algorithm as the CNR is 




Ultimately this experiment highlights the different factors that make an objective 
function challenging for an optimization algorithm. First, as CNR increases, the responses 
from the objective become less noisy and it becomes easier to find the global maximum of 
the objective. Additionally, the smoothness of the objective plays a significant role. Both 
the Rastrigin and the Easom models have very sharp changes across the parameter space, 
and as such prove more challenging for the UCB(0.4) algorithm. This is especially true for 
the Easom model, as so much of the parameter space is flat, and give little information to 
the algorithm. Without accidentally sampling close to the global maximum, it is unlikely 
it will find the optimal parameters. Lastly, all objectives became more difficult when the 
dimension was increased from 2D to 3D, a trend that will undoubtably continue as higher 
dimensional objectives are designed. 
2.5.6 Viral expression and electrode placement 
After the completion of the study, histology was performed to verify the location 
of the electrode and viral vector expression. Rats were transcardially perfused with 0.9% 
saline followed by 4% paraformaldehyde in 0.1M phosphate buffer after they were deeply 
anesthetized with a lethal dose of Euthasol (100mg/kg, Virbac, Fort Worth, Tx, USA). Rat 
heads were post-fixed overnight with the electrodes and ferrules in place. Brains were 
subsequently dissected out and transferred to 30% sucrose in phosphate buffered saline 
until they sank. Then, brains were sectioned coronally at 40 µm using a cryostat and 
mounted on glass slides with Vectashield DAPI (Burlingame, CA, USA) mounting 
medium for visualization of nuclei. Slides were imaged to visualize the fluorescent tags in 




SimplePCI software (Leica Microsystem, Buffalo Grove, IL). Hippocampal sections were 
mounted and stained using Cresyl Violet (C5042 Sigma-Aldrich, St. Louis, MO), 
coverslipped and imaged using a Nikon DS-fil color digital camera on a Nikon E400 
microscope and NIS-Elements software (Nikon Instruments, Inc., Melvile, NY, USA). 
Expression of the GFP opsin reporter was visible in neurons in the medial septum 
(Figure 2.15A) as well as in processes and terminals in many areas of the hippocampus 
(Figure 2.15B) including the  stratum oriens, stratum  radiatum (Figure 2.15C) and the 
hillus of the dentate gyrus (Figure 2.15D). The electrode track was visible in the CA1 layer 





Figure 2.15: Viral expression and electrode placement.  
(A) Micrograph through the septal area showing GFP opsin reporter expression in neurons 
in the medial septum. (B)  Micrograph through the dorsal hippocampus showing GFP opsin 
reporter expression in many areas of the hippocampus. (C) Micrograph in the CA1 region 
showing GFP opsin reporter expression in processes and terminals in the stratum oriens 
and stratum radiatum. (D) Micrograph showing GFP opsin reporter expression in processes 
and terminals in hillus region of the DG. (E) Micrograph of Cresyl Violet stained section 
through the hippocampus showing an electrode track (arrow) in the CA1 pyramidal layer. 
Abbreviations: MS: medial septum, LS: lateral septum, ac: anterior commissure, CA1: 
pyramidal cell layer 1, CA3: pyramidal cell layer 3, DG: dentate gyrus, SO: stratum oriens, 
SR: stratum radiatum, H: hillus, GCL: granule cell layer. Scale: A, B and E: 1 mm; C and 





CHAPTER 3. APPLICATION OF THE FRAMEWORK FOR 
SETPOINT OBJECTIVES 
3.1 Introduction 
In Chapter 2 we designed and characterized and optimization algorithm to find the 
medial septum optogenetic stimulation settings that maximize hippocampal gamma power. 
However, it may not be ideal, or even safe, to maximize a specific neural feature or 
behavioral measures. In fact, the goal may be to find the stimulation setting that modulates 
the electrophysiological or behavioral measurement to a specific value somewhere between 
the maximum and the minimum.  
In the second application of this framework, we reframe the task to finding the 
stimulation parameters that modulate hippocampal gamma to a desired setpoint. We first 
adapt our framework for setpoint objectives, and use the models constructed in Chapter 2 
to further explore the implications of this change. We then evaluate the UCB(0.4) algorithm 
on this setpoint optimization problem, before validating it in vivo. 
3.2 Methods 
3.2.1 Surgery, virus injection, and electrode implant 





3.2.2 Setpoint objective function 
According to the first step in this framework, we return to the ground-truth models 
mapping stimulation amplitude (𝑎), frequency (𝑓), and pulse-width (𝑝), to induced 
hippocampal gamma power (𝑌"#$$#): 
 𝑌"#$$# = 𝐹(𝑎, 𝑓, 𝑝) (3.16) 
To construct a setpoint objective function we apply the following transformation, 
 −1 ∗ 𝑎𝑏𝑠4𝑌"#$$# − 𝑌E59 (3.17) 
where 𝑌E5 is the desired setpoint. This transformation has the effect of centering the model 
so that the setpoint is now at 0, and “folding” the model so that regions where the output is 
above the setpoint are flipped about the zero-axis. 
3.2.3 Simulation experiments 
The BaO algorithm found to have the best performance for the maximization 
experiments in Chapter 2 was used for the setpoint optimization experiments. This 
algorithm was used to find the max of the setpoint objective applied to the simulation model 
for subject R1. For each of three setpoints (0.15, 0.45, and 0.8), 30 trials were performed 





3.2.4 In vivo experiments 
Setpoint optimization was validated in two subjects (R5 and R6). Here, the 
objective function was set to find the stimulation parameters that modulate hippocampal 
gamma power to either 1.5, 3.0, or 20 times a baseline measurement. The subjects were 
connected to the data acquisition system and LED stimulator as described for the gamma 
maximization experiments. The LFP was recorded for 5 minutes at baseline and 
hippocampal gamma power was calculated on non-overlapping 5 second segments. The 
median value was then used as the baseline for the rest of the experiment. 
The optimization phase consisted of 10 burn-in samples followed by 30 samples 
using UCB (0.4). Each sample consisted of 5 seconds of stimulation followed by a 25 
second washout. For the validation phase, the estimated optimal stimulation parameters for 
the three setpoints were applied in a random order ten times each for a total of 30 samples. 
Sample timing was as in the optimization phase. 
3.3 Results 
3.3.1 Setpoint objective applied to ground-truth models 
The application of the setpoint transformation to the model mapping stimulation 
parameters to hippocampal gamma power is shown in Figure 3.1. Figures 3.1A-C, show 
the setpoint objective functions at three different setpoints (0.15, 0.45, 0.8, where 1.0 is the 
maximum gamma power) for subject R1. It can be seen that, rather than a single stimulation 




of stimulation parameters that would modulate hippocampal gamma to the desired setpoint. 
When the original 𝑌"#$$# model is projected onto a 2D surface, this level set can be drawn 
as a contour line where the model outputs, 𝑌"#$$#, are equal. Based on this, we would 
expect that optimization using this objective function could converge to a range of 
different, but effectively equivalent, stimulation parameters. When comparing the 
objectives for the three different setpoints it can be seen that the width of the band around 
the contour lines varies. When the setpoint is 0.15, the band is very wide showing that there 
are a number of stimulation patterns that have an effect that is near that of those on the 
level set of optimal solutions. In contrast, for the objective function with a setpoint of 0.45, 
the width of the band is narrower. Figure 3.1D compares the level set solutions for the 
three setpoints across the three subjects R1-3. For a given setpoint, the level set solutions 
for the three subjects are in the same general region of the parameter space. However, there 
is a degree of subject-specific-variability. This indicates the need for an optimization 





Figure 3.1: Setpoint objective functions can have a level set of equivalent solutions. 
(A-C) The three setpoint objective functions for subject R1. Black line is a polynomial 
regression along the top 100 objective values and is intended for illustration, not an exact 
representation of the level set solution. (D) The three set point objective functions for R1 
(solid lines), R2 (dashed lines), R3 (dotted lines).     
3.3.2 Using framework to prototype optimization for a setpoint objective 
We then adapted the previously described simulation platform to prototype data-
driven optimization for a setpoint objective function. Building on our previous results, we 
focused our analysis on the UCB(0.4) algorithm. Figure 3.2A shows the search trajectories 
for each setpoint using the model constructed from subject R1. Looking at a single 




algorithm converged on stimulation amplitudes and frequencies along the corresponding 
level set. Over the course of the optimization, there are samples in which the estimated 
optimal frequency and amplitude change somewhat dramatically as they switch to a nearly 
equivalent point on the level set. However, given that the simulation platform can rapidly 
run multiple trials under identical conditions, the overall range of behavior of the 
optimization system could be observed. As expected, across 12 independent trials for a 
setpoint the optimization algorithm converged to a range of different stimulation 
parameters, all of which had a similar effect on hippocampal gamma power. The optimal 
parameters estimated by the optimization system compared to the ground truth level set 
solutions are shown in Figure 3.2B. For the highest setpoint, the optimal estimated 
parameters are grouped tightly around the level set solution, while the lower two setpoints 
have a wider distribution. This is likely due to the flatness of the objective function as 
described in the analysis of the ground truth model. Figure 3.2C shows the effect of the 
stimulation parameters selected by the optimization system when applied to the ground 
truth model. For both the low (0.15) and high (0.80) setpoints, the optimization algorithm 
was able to reliably identify stimulation parameters that modulated hippocampal gamma 
to the desired value. However, for the middle setpoint (0.45), there was more variability in 






Figure 3.2: Simulation results for setpoint optimization for hippocampal gamma 
power. 
(A) The search trajectories for three representative trials of setpoint optimization. The grey 
box indicates the 10 burn-in samples. Bold colored lines are the estimated optimal 
stimulation parameter at each sample. Thin black lines are the actual samples evaluated by 
the optimization algorithm. (B) The estimated optimal stimulations parameters for each of 
the setpoints shown in filled circles along with the level set contour lines for each setpoint. 
(C) The ground-truth effect on hippocampal gamma power according to the model. As in 
the maximization simulations, the outputs of the model are linearly scaled between 0-1. 
Each circle represents a trial. Black line and error bars represent the mean and standard 





3.3.3 In vivo optimization for setpoint 
After prototyping setpoint optimization in silico, we then deployed the algorithm 
in vivo. The setpoints used were 1.5, 3, and 20 times the baseline gamma power. Figure 
3.3A shows the search trajectory for a representative trial in subject R5. As expected from 
the analysis of the ground-truth models and the simulation experiments, synchronized 
shifts in the estimated optimal stimulation parameters are seen as the optimization system 
selects statistically equivalent solutions from the setpoint level set. In this trial, for the 
larger setpoints the estimated optimal stimulation parameters had higher frequencies, and 
the estimated optimal amplitudes did not show a specific pattern. While this trial shows a 
general decrease in the estimated optimal pulse-width as the setpoint increases, this is not 
consistent between trials/subjects. In Figure 3.3B, we show the optimal stimulation 
parameters estimated for two trials consisting of optimizing for each setpoint in two 
subjects (R5 and an additional subject R6). The lines connect the three setpoint 
optimizations conducted in a row as part of one trial within subject. As predicted by the 
simulation experiments, the two lower setpoints resulted in trials with either high amplitude 
and low frequency, or vice versa. For the largest setpoint, the optimization is equivalent to 
a maximization problem, and therefore the estimated optimal stimulation parameters are 
close together. 
We then evaluated the estimated optimal stimulation parameters for each setpoint 
in a randomized test phase. Results for subject R5 are shown in Figure 3.3C. For the first 
setpoint, 1.5, the estimated optimal stimulation parameters were able to reliably modulate 




3.0, in one trial the estimated optimal stimulation parameters overshot the desired setpoint, 
while in the other trial the estimated optimal stimulation parameters undershot the desired 
setpoint. This mirrors the wider trial-to-trial variability seen with the setpoint of 0.45 in the 
simulation experiments. For the final setpoint, 20.0, the estimated optimal stimulation 
parameters were only able to modulate hippocampal gamma to 5.2- and 5.4-times baseline. 
This underscores the limitation of setpoints to within a physiologically possible range. 
Finally, Figure 3.3D shows the wideband PSD for the estimated optimal stimulation 
parameters for each setpoint. The PSDs for all three setpoints have peaks within the gamma 
range (33-55Hz). However, the primary peaks and harmonics are not necessarily aligned 
outside of the gamma range for the three setpoints as the respective stimulation frequencies 
were 11.7, 18.4, and 37.9Hz. Focusing on the gamma range in Figure 3.3E, there is an 
increase in power for the frequencies around 37Hz, maximizing the area under this region 
of the PSD using this constrained stimulation parameter space. Results for additional trials 





Figure 3.3: In vivo setpoint optimization of hippocampal gamma power. 
(A) Search trajectory for a representative trial in subject R5. Grey boxes represent the 10 




sample. Thin black lines are the actual samples evaluated by the optimization algorithm. 
The squares at the end of each trajectory for amplitude and frequency correspond to those 
in Figure 9B. (B) Trajectory of the estimated optimal stimulation parameters across the 
thee setpoints within a trial for subjects R5 and R6. The estimated optimal parameters for 
the three setpoints within each trial are connected with a line. (C) Results of the validation-
phase for subject R5. Lines connect the three tested stimulation parameters found during 
each independent experiment session. Vertical black lines show the standard deviation and 
each marker is an individual sample. ‘X’ shows the setpoint target for baseline multiples 
1.5 and 3. Marker for the baseline multiple of 20 would be off scale. (D) Mean wideband 
PSD for the test phase of a representative trial. (E) Gamma range PSD. Shaded regions 
indicate standard deviation across trials. 
3.4 Discussion 
To test the predictive power of the framework on other objective functions, we 
adapted the optimization algorithm to instead modulate hippocampal gamma power to a 
desired setpoint. While the mathematical transformation to create a setpoint objective 
function was relatively simple, the ground-truth models and the overall simulation platform 
provided a valuable opportunity to more extensively study the implications of this 
transformation. In the simulation, the two key findings were, 1) rather than a single 
optimum there was a level set of stimulation parameters that were effectively equivalent, 
and 2) the algorithm performed worst on the middle setpoint of the three. Both these 
characteristics were observed in vivo. First, the different stimulation parameters for a given 
setpoint were markedly different but performed similarly, providing opportunities for 
additional constraints (e.g. find the stimulation parameters for a setpoint with the lowest 
energy consumption). Second, by folding the objective function on that setpoint, the overall 
contrast between the minimum and the maximum was smaller, while the noise remained 
the same. This results in a lower contrast-to-noise ratio, making the optimization problem 




The extension of the framework to setpoint objectives offers the potential for even 
more precise brain stimulation therapy and more tightly controlled experimental 
interventions.  
3.5 Supplement 
3.5.1 Setpoint results for other experiments 
Figure 3.4 shows the search trajectories for the three trials not shown in Figure 
3.3. These include the first trial for subject R5 and both trials for subject R6. Figure 3.5 





Figure 3.4: In vivo setpoint optimization trajectories. 
Search trajectory for a representative trial 1 in subject R5 and trials 1 and 2 for subject R6. 
Gray boxes represent the 10 burn-in samples. Bold colored lines are the estimated optimal 
stimulation parameter at each sample. Thin black lines are the actual samples evaluated by 
the optimization algorithm. The markers at the end of each trajectory for amplitude and 





Figure 3.5: Results of the validation-phase for subject R6. 
Lines connect the three tested stimulation parameters found during each independent 




individual sample. ‘X’ shows the setpoint target for baseline multiples 1.5 and 3. Marker 





CHAPTER 4. APPLICATION OF THE FRAMEWORK FOR 
STATE-DEPENDENT OBJECTIVES 
4.1 Introduction 
In Chapters 2 and 3 we considered the response to stimulation to be noisy, but static. 
In other words, the stimulation setting that is optimal on average does not change. 
However, this may not always be the case. For example, it is well established that the effect 
of DBS for PD patients can vary based on the patient’s medication level and general 
physiological state. As a result, the optimal stimulation setting will dependent on the 
underlying neural state. In order to deliver continually optimal stimulation, the algorithm 
would need to learn how the effect of stimulation changes with the underlying state, and 
adjust the stimulation settings accordingly.  
To explore how data-driven optimization can be extended to state-dependent 
objective functions, we construct a model system by delivering medial septum optogenetic 
stimulation at varying levels of isoflurane anesthesia and measuring hippocampal gamma 
power. While the mechanism of isoflurane anesthesia is not full elucidated, the general 
hypothesis is that it decreases the conductance of potassium channels, increasing the 
refractory period of the neurons. We first investigate how anesthesia alters the response to 
stimulation, and then propose an extension of Bayesian optimization that learns a state-






4.2.1 Surgery, virus injection, and electrode implant 
Surgical details are as described in Chapter 2, Section 2.1. 
4.2.2 Grid search experiment under varying levels of anaesthesia 
Neural modulation data was collected under two distinct neural states: while the 
animal was freely behaving, and while subjects were under 2-3% isoflurane anesthesia. In 
each condition, a grid search consisting of six frequencies (5, 7, 11, 17, 23, 29, 35 Hz) at 
six amplitudes (0, 10, 20, 30, 40, 50 mW/mm^2) was conducted. Each stimulation 
consisted of a pulsatile 4ms square-wave delivered for 4 seconds, and was applied in 
sequences of 5 stimulations (20s) separated by 40s for washout. 
4.2.3 Neural feature calculation 
Neural signals from CA3 and CA1 were recorded at 24414Hz and down-sampled 
to 2 kHz. Each 4 second stimulation epoch (X1) and 4 second pre-stimulation epoch (X) 
was segmented along with the corresponding stimulation parameters (U1). The power 
spectral density was then estimated using the multi-taper method and summed to measure 
the overall power for each of the canonical spectral bands (delta: 1-4 Hz, theta: 4-7 Hz, 
alpha: 8-12 Hz, beta: 13-31 Hz, and gamma: 32-50 Hz). The power in each of these bands 





4.2.4 Static GP model fitting 
The static Gaussian process was modeled as described in Chapter 2, section 2.4. 
4.2.5 State-dependent Gaussian process model 
To test optimization approaches on a state-dependent model, we constructed a state-
dependent simulation platform from the stimulation and neural state data. The core of the 
simulation platform is a Gaussian process model mapping pre-stimulation neural state X0 
and stimulation parameters U1 to the neural state during stimulation X1. Using this 
Gaussian process, a set of stimulation parameters U1 can be sampled to produce a draw 
from a normal distribution: 
 𝑋) = 𝐺𝑃(𝑈)|𝑋D) = 	𝒩(𝜇(𝑈)|𝑋D), 𝜎(𝑈)|𝑋D)) (4.1) 
where 𝜇 and 𝜎 are the output of the Gaussian process. In this formulation, the neural state 
during stimulation is a function of both the stimulation parameters and the pre-stimulation 
neural state  
4.2.6 State-dependent Bayesian optimization 
For any general optimization problem, the goal is to identify the argument U1 that 








Since the objective function is stochastic, we are limited to gradient free optimization 
methods. Moreover, given the time- and resource-intensive nature of evaluating the effect 
of stimulation, data-efficient optimization algorithms are well-suited to this problem. 
Using the state-dependent simulation platform, we compared two optimization 
algorithms. The first was the standard implementation of BaO. For an in-depth treatment 
of BaO, see [44]. Briefly, the BaO algorithm is a model-based, gradient-free optimization 
algorithm. A small number of burn-in samples are drawn from the stimulation parameter 
space. The stimulation parameters U1 and neural state during stimulation X1 are used to fit 
a Gaussian process model. An acquisition function is then applied to the Gaussian process 
which weighs value of sample based on the magnitude of the expectation for and the 
uncertainty. In this case we used the UCB acquisition function: 
 𝐻89: = 	𝜇(𝑥) + e𝜅&𝜎(𝑥) (4.3) 
where the sequence 𝜅& was defined as 𝜅& = 2 log k
&#;#
<
l, with 𝑡 being the number of 
samples collected so far. In other words, the emphasis on exploration increases with each 
additional sample. The set of stimulation parameters with the highest value for the 
acquisition function is then sampled. The new set of stimulation parameters and 
corresponding neural state during stimulation is then used to update the model, and the 
process is repeated until either stopped or a convergence criterium is met. 
By construction, one limitation of the standard implementation of BaO is that it 




optimize. In other words, if the optimal set of stimulation parameters changes as a function 
of the neural state, BaO is likely to converge to the optimal parameters for the pre-
stimulation neural states that more prevalent, converge to a set of parameters that is a 
weighted average of the different optima across states, or not converge at all.  
To address the limitations of the BaO algorithm we extended the algorithm to not 
just learn the effect of the stimulation, but to take into account the pre-stimulation state 
when stimulation is applied. This approach, state-dependent Bayesian optimization 
(SDBO), still uses a Gaussian process to approximate the objective function which maps 
the stimulation parameters U1 and the pre-stimulation neural state X0 to the neural state 
during stimulation. During the learning phase, SDBO 
4.2.7 Simulation experiments 
Both optimization approaches, BaO and SDBO, were evaluated in a two-phase 
experiment. In the first training phase, the algorithms interact with the simulation platform 
by sampling stimulation parameters, measuring their effect on neural state, and updating 
their models. In the test phase, the optimization algorithms apply their learned policies 
without exploration to maximize the neural state in the simulation platform. Both phases 
consist of 100 interactions with the simulation platform, and each train-test cycle is 







4.3.1 Effect of stimulation changes under isoflurane anaesthesia 
Comparing the cross-validated NMSE across all three models characterized the 
contribution of the stimulation parameters, the pre-stimulation neural state, and the 
combination of both to predicting the during-stimulation neural state. Based on this 
analysis we found that different spectral bands have different levels of state- vs. 
stimulation-dependent effects (Figure 4.1). For the band with the lowest frequency, delta 
(1-4 Hz), the static model (U1) performed worse than both the state (X0) and joint ([U1, 
X0]) models, indicating that the pre-stimulation state is the best predictor of the during-
stimulation state, and that stimulation has little to no effect. Both theta (4-7 Hz) and alpha 
(8-15 Hz) did not have NMSEs that were significantly lower than 1, indicating that neither 
the stimulation parameters (U1) or the pre-stimulation state (X0) were significant predictors 
of during-stimulation state (X1). In contrast to the previously mentioned spectral bands, for 
beta power (16-31 Hz), the static model and the joint model both had significantly lower 
NMSE than the model with state alone. This suggests that the best predictor of during-
stimulation beta power is the stimulation parameters. Finally, for gamma power, both the 
static model and the state model had similar NMSEs, while the joint model was an 
improvement over both. This finding suggests that the effect of stimulation parameters on 
during-stimulation neural state is directly influenced by the pre-stimulation neural state. 
Based on these findings, successful optimization of gamma power requires adjusting 





Figure 4.1: Gaussian process regression model accuracy for stimulation parameters, 
baseline state, and joint predictors. 
Each set of bars indicates the mean NMSE across 20-folds of cross-validation ± standard 
error. Red stars over gamma show the set of significance tests (t-test, p < 0.05) that 
demonstrate hippocampal gamma is dependent on stimulation parameters and pre-
stimulation state. 
4.3.2 Modelling identifies gamma power as dependent on anaesthetic levels 
The change in how in the mapping from stimulation parameters to during-
stimulation state based on pre-stimulation state is demonstrated in Figure 4.2.  This figure 
shows the mapping from stimulation parameters to during-stimulation gamma power is 
altered as gamma increased from the lowest value observed during isoflurane anesthesia to 
the highest value observed while the subject is freely behaving. Initially, at the lowest pre-
































Static: Xk1 = F(Uk1)
State:  Xk1 = F(Xk0)




stimulation gamma power are 35 Hz at 50 mW/mm2. However, as pre-stimulation gamma 
power increases, a local maximum forms around 15 Hz at a lower amplitude of 25 
mW/mm2. As the pre-stimulation gamma approaches the highest value observed in the 
freely behaving subjects, this local maximum becomes the global maximum. Tracking the 
progression of the stimulation parameters corresponding to this global max demonstrates 
that an optimization algorithm to maximize gamma power should take into account the pre-
stimulation gamma neural state. 
 
Figure 4.2: Change in gamma at different values of baseline gamma power.  
(A-D) Each surface is a cross-section showing the effect of stimulation on the change in 
hippocampal gamma at different levels of baseline gamma power. Baseline gamma 





4.3.3 Using framework to prototype state-dependent Bayesian optimization 
 Both the BaO and SDBO algorithm were applied to the platform which simulates 
the stochastic effect of stimulation parameters on during-stimulation state, but changes the 
effect of the stimulation parameters based on the pre-stimulation state. Figure 4.3A shows 
the median and quantiles of the during-stimulation gamma power for both algorithms. 
Initially, when the pre-stimulation state is low (~0-1.5x10-10 V2/Hz) the policies learned by 
both algorithms perform comparably well. However, once the pre-stimulation state rises 
above 1.5x10-10  V2/Hz, SDBO performs substantially better. In other words, the parameters 
selected by SDBO are able to induce a higher during-stimulation gamma state than the 
single set of stimulation parameters learned by BaO. As the pre-stimulation neural state 
then decreases, both algorithms again perform similarly. 
Figure 4.3B compares the policies learned by both algorithms to the optimal 
ground-truth policy from the simulation platform. The optimal policy (black line) shows 
that for low gamma pre-stimulation states, the stimulation parameters that most increase 
gamma are at 50 I and 35 Hz. However, as the pre-stimulation gamma transitions from  
1.5x10-10 V2/Hz  and 5x10-10 V2/Hz the stimulation parameters that most increase gamma 
during stimulation are around and intensity of 25 mW/mm2 and a pulse frequency of 15 
Hz. While the policy learned by SDBO tracks the change in optimal parameters (orange 
line), BaO selects a single parameter that is closer to the optimal for the states with lower 
gamma power, but typically falls in between the optimal parameters for lower- and higher-






Figure 4.3: Performance and behavior of BaO and SDBO during test phase in silico. 
(A) The during-stimulation gamma power for BaO (green) and SDBO (orange), patches 
indicating the quartiles across 30 trials. Black line shows the baseline gamma power before 
stimulation. (B-C) The distributions of static parameters learned by BaO, and the policies 
learned by SDBO. Black line is the optimal policy from the ground truth model. 
4.4 Discussion 
In this study, we found that the mapping from stimulation parameters to gamma state 
during stimulation is dependent on a pre-stimulation gamma neural state. We then created 
a platform that simulated the effect of medial septum optogenetic stimulation on 
hippocampal gamma power, based on a changing pre-stimulation gamma state. Using this 
platform, we then compared two algorithms for optimizing stimulation parameters to 
maximize gamma state: the standard implementation of static Bayesian optimization, and 




4.4.1 Stimulation parameters are not one-size-fits-all-states 
It is a reasonable hypothesis that the effect of applying stimulation to a neural 
system is going to be dependent on not only the characteristics of the stimulation applied, 
but also the current state of the neural system. When we tested this hypothesis in our medial 
septum optogenetic stimulation model we found that this was not always the case. For some 
spectral bands used as measures of neural state, the prediction of the next state X1 is entirely 
dependent on: the current state X0 (delta), the stimulation parameters U1 (alpha), both 
(gamma), or neither (theta and beta). While it would have been interesting had all 
biomarkers been state-dependent within our parameters space, the approach we used of 
comparing the NMSE of GP regression models is relatively non-conservative. Specifically, 
if the change in pre-stimulation neural state causes a shift in the mapping from stimulation 
parameters to neural state without changing the location of the global extrema it would still 
register as state-dependent. In the context of optimization, this would not be relevant as the 
optimal parameters would not change. However, this could play a role when adapting this 
approach to control around a setpoint. 
4.4.2 Framework can be extended to state-dependent objectives  
Using our simulation model of the state-dependent effect of medial septum 
optogenetic stimulation we tested standard Bayesian optimization (BaO) and a state-
dependent extension (SDBO). We found that SDBO out-performed BaO when the mapping 
from stimulation parameters to gamma state is changing. The BaO algorithm was limited 




policy based on the weighted average of states and their optimal parameters. i.e., the 
learned policy is between the two true optimum, but closer to the optimum for the states 
more encountered. In contrast, SDBO learns a state-dependent policy that does not conflate 
optima at different states. This approach could be further extended to use additional 






CHAPTER 5. APPLICATION OF THE FRAMEWORK FOR 
SAFETY CRITICAL OPTIMIZATION 
5.1 Introduction 
 While neural modulation can be an effective therapy, it can also cause side effects. 
For optimization to be used in clinical practice, it needs to account for subject- specific 
safety considerations. While DBS is generally well-tolerated in patients, regions of the 
parameter space that are optimal in some subjects can produce unwanted and 
uncomfortable side-effects in other subjects. These include muscle contractions [55], voice 
changes [56], and abnormal sensations. While side effects or returning symptoms caused 
by a change to the stimulation setting may be briefly tolerable under the supervision of a 
clinician, they could be unsafe or detrimental during daily living activities [57]. As a 
consequence, it will be critical to design data-driven that can actively learn and avoid 
unsafe parameter space regions for any automated or unsupervised optimization 
approaches. This can be accomplished by building on recent work demonstrating how 
learnable safety constraints can be integrated with a Bayesian optimization approach to 
safely and efficiently navigate a parameter space [58]. 
Recent work in the field of optimization has produced algorithms specifically 
designed for safety-critical optimization [59]. Many systems in the aviation and industry 
require a tuning and optimization process to achieve optimal performance. However, if the 




optimization methods can be implemented across a range of algorithm types (e.g., 
evolutionary or gradient approximation) we limit our focus to Bayesian optimization 
approaches. In the context of neural modulation, a safety-critical optimization algorithm 
has three goals, exploitation – finding the best stimulation setting, exploration – testing 
stimulation settings with high uncertainty, and safety – avoiding regions of the parameter 
space that have a high likelihood of being unsafe. The exploitation and exploration are 
based on the surrogate model of the objective, as in Chapters 2-4, while the safety can be 
based on the same surrogate model, a model of a specific safety metric, or multiple safety 
metrics.  
 This chapter extends the previously described framework [37] to prototype and 
deploy a Bayesian optimization algorithm with learnable safety constraints called META-
SAFE (Figure 5.1). We designed, characterized, and deployed this algorithm in normal 
rats undergoing a spatial object recognition (SOR) memory task while receiving 
hippocampal stimulation. The stimulation paradigm used was originally developed to 
reduce seizures in the rat tetanus toxin model of temporal lobe epilepsy [60], and was later 
shown to impair performance on the SOR task at sufficiently high stimulation amplitudes 
[61]. Using this model system, we designed and validated an optimization algorithm with 
the goal of efficiently maximizing the stimulation while carefully avoiding regions of the 






Figure 5.1: META-SAFE design framework. 
The design framework was applied in four phases. 1) Data was collected from an initial 
cohort of subjects that approximate the diversity in the general population by applying 
different stimulation settings and measuring the resultant performance on the memory task. 




level, could act as a proxy for the original subject, but with advantage that testing a 
stimulation in silico was nearly instant relative to in vivo. 3) Instead of prototyping and 
refining the META-SAFE algorithm on real subjects, the different configurations of 
META-SAFE were rapidly evaluated on each of the proxy simulation models. 4) The 
configuration of META-SAFE that performed best across the proxy simulation models was 
then validated in vivo in a new cohort of subjects. 
5.2 Methods 
The design framework was applied in four phases. 1) Data was collected from an 
initial cohort of subjects that approximate the diversity in the general population by 
applying different stimulation settings and measuring the resultant performance on the 
memory task. 2) The data from each subject was used to create a simulation model that, on 
a statistical level, could act as a proxy for the original subject, but with advantage that 
testing a stimulation in silico was nearly instant relative to in vivo. 3) Instead of prototyping 
and refining the META-SAFE algorithm on real subjects, the different configurations of 
META-SAFE were rapidly evaluated on each of the proxy simulation models. 4) The 
configuration of META-SAFE that performed best across the proxy simulation models was 
then validated in vivo in a new cohort of subjects. 
5.2.1 Data collection 
5.2.1.1 Subjects and surgery 
Subjects underwent a single survival surgery to implant a 16-channel MEA in the 
CA3 and CA1 regions of the hippocampus. Implantation details are identical to those in 
the second survival surgery described in Chapter 2, Section 2.1, with the omission of the 




5.2.1.2 Asynchronous distributed stimulation 
The stimulation pattern consisted of symmetric square wave biphasic pulses with 
400 µs per phase on eight stimulating contacts [60]. Stimulation was applied fully 
asynchronously where each contact had a pulse frequency of 7 Hz with a phase offset of 
)
F∗G
𝑠. Stimulation was voltage controlled with amplitudes ranging from ±0-5 V. 
5.2.1.3 Spatial object recognition (SOR) task 
The SOR task is a well-established behavioral task to test object recognition 
memory in various animal species [62]. The task relies on the innate preference of rats for 
novel objects and changes in object location. Before starting the SOR experiments, the 
implanted rats were habituated to a 2’x1.5’ open-field SOR box for 5 minutes per day for 
three days. Practice objects were placed in the SOR box on the third day to determine 
whether the subjects were willing to explore the objects or additional habituation was 
necessary. 
Each SOR task consists of four phases: acclimation, familiarization, delay, test. 
(Figure 2). In the acclimation phase, the rat was moved to the testing room 30 minutes 
before the SOR task is performed. Meanwhile the SOR box was thoroughly cleaned with 
70% isopropyl alcohol to remove any olfactory signals, and three distinct objects were 
placed in the corners of the exploration area. At the end of the acclimation phase, the 
headstage was connected to the electrode on the subject, who was then moved to a region 
of the SOR box separated from the exploration area by an opaque divider. The headstage 




was started. After 1 minute of stimulation, the divider was temporarily removed to begin 
the familiarization phase. The subject was allowed to interact with the objects for 3.5 
minutes, before being again separated from the exploration area by the divider for 3 
minutes. During this delay phase, the exploration area and the objects were thoroughly 
cleaned with 70% isopropyl alcohol to remove any olfactory signals. During the testing 
phase, the subject was returned to the exploration area and allowed to explore the objects 
for 3.5 minutes. The rat was then removed from the exploration area to complete the task 
The orientation of interchanged objects was counterbalanced among the three 
corners to prevent any bias. A camera placed on the top of the SOR box was used to capture 
the video of the familiarization and the testing phases. SOR experiments were performed 
in a sound-isolated room with limited red light.  
 
Figure 5.2: Overview of the SOR task. 
Starting with the habituation phase, the subject is allowed to acclimate to the room in their 
home cage for 30 minutes. The subject is then connected to the headstage and placed in the 
SOR box, separated from the objects by an opaque removable divider. In the familiarization 
phase, stimulation is started and after 1 minute the divider is temporarily removed to allow 
the subject to interact with the three objects labeled A, B, and C. After 3.5 minutes the 




and the objects are returned with two of them in swapped positions. After 3 minutes, the 
divider is again removed for the subject to interact with the objects for 3.5 minutes. Each 
SOR task produces a single DS measurement. 
5.2.1.4 Discriminant score 
Discrimination score (DS) was used to quantify the animal’s memory performance. 
DS is defined as the difference in exploration time for interchanged objects and exploration 
time for stationary object divided by the sum of exploration time for interchanged objects 
and exploration time for stationary object: 
 
𝒎𝒆𝒂𝒏(𝑻𝑩, 𝑻𝑪)	 − 𝑻𝑨
𝒎𝒆𝒂𝒏(𝑻𝑩, 𝑻𝑪) + 𝑻𝑨
 (5.1) 
Where 𝑻𝑨, 𝑻𝑩 and 	𝑻𝑪, represent the time the subject spent interacting with the three 
objects. The score ranges from -1 to +1. A score of +1 indicates preference only for the 
interchanged objects and a score of -1 indicates preferance only for the stationary object. 
A score of 0 suggests equal preferenence for all three objects and is indicative of no 
memory. Exploration of an object was defined as the orientation of animals’s snout directed 
towards the object with the whiskers actively twitching, which suggests sniffing. Any other 
interactions such as running around the object, playing with the object, sitting or climbing 
on the object was not recorded as exploration. Videos of the SOR task were scored by a 
blinded observer using Spike2 (Cambridge Electronic Design Limited, Cambridge, 
England) to annotate the start and stop of each interaction with an object.  
Only one sample was collected per day to prevent any interaction between 




headstage was disconnected, an object fell, or the experiment was otherwise interupped 
were discarded. SOR tasks where stimulation caused an adverse reaction: electrographic 
afterdischarges, seizures, etc. were stopped and scored with a DS of -1 to discourage the 
algorithm from further sampling from that region of the parameter space. 
5.2.1.5 Collected data and data augmentation 
The data used in the design framework was collected from grid and optimization 
experiments for 4 subjects conducted as part of a previous study and the 2 subjects included 
in the standard Bayesian optimization in vivo experiments in Chapter 5, Section 3.4.1. For 
some subjects, the maximum amplitude tested (±4 V) did not disrupt memory, i.e., the 
average DS did not drop below 0. In these cases, the dataset was augmented with artificial 
data points at ±6 and ±7 V, to create a region of the parameter space with an average DS 
of approximately 0. 
5.2.2 Ground-truth models for simulating optimization 
5.2.2.1 Ground-truth models of DS 
For each subject, the input stimulation amplitude and corresponding output DS 
were fit to a Gaussian process (GP) regression model [45] as described in [37], [63]. The 
GP was composed of mean and covariance functions: 





 Σ = 	k(𝐱, 𝐱!) (5.3) 
where 𝑥 is a vector of the data used to construct the model, and 𝑥! is an unlabeled sample 
point. In this application the input to the model was a single dimensional parameter space 
representing the stimulation amplitude discretized on ±0.05 V intervals. The output of the 
model was the DS drawn from a Gaussian distribution. 
 𝐷𝑆	~	𝒩(µ, Σ) (5.4) 
The GP was a constant mean function and a third order Matérn kernel with automatic 
relevance determination for the covariance: 
 𝑘4𝑥/ , 𝑥09 = 𝜎1241 + √3𝑟9 exp4−√3𝑟9 (5.5) 
where 𝜎12 is the variance of the output and:  







where 𝜎$2  is the length scale hyperparameter describe the variance of the stimulation 
amplitude parameters, 𝑥$, [45]. In other words,	𝜎$2  represents how much the expectation 
can vary between adjacent stimulation amplitudes. Each model was individually reviewed 
and model hyperparameters (mean, length scale, signal noise, measurement noise) were 





5.2.2.2 Discrimination area (DA) objective function  
In previous studies, it was shown that optimizing stimulation amplitude based on 
DS produced a trivial optimum close to 0.0 V – i.e., no stimulation. To address this, the 
objective function used in this study was the discrimination area, or the DS multiplied by 
the stimulation amplitude. By construction, this objective function possessed several 
convenient properties. Specifically, when either the amplitude or DS were equal to zero, 
the DA was also zero. However, at a midpoint when a stimulation with an amplitude greater 
than zero is applied and does not completely disrupt memory, the DA is positive. Therefore, 
since the Matérn kernel of the GP is differentiable, according to Rolle’s theorem, there 
must exist at least one stimulation amplitude for which the derivative is zero, which based 
on previous data. is likely a non-trivial maximum of the objective function. 
5.2.3 Meta-Bayesian optimization with learnable safety constraints 
5.2.3.1 Bayesian optimization 
The Bayesian optimization algorithm used in this study was based on a GP model 
and an upper confidence bound (UCB) acquisition function as described in [44]. The 
algorithm initializes by sequentially applying a set of burn-in stimulation settings 
(amplitude). The objective function, DA, is calculated and the data is fit to a surrogate GP 
model. The acquisition function was then used to quickly identify regions of the parameter 
space where the model predicts the average DA would be high (exploitation), but also had 
a large uncertainty with the statistical potential for even higher DA value (exploration). 




 𝐻89: =	𝜇?+(𝑥) + e𝜂𝜅&𝜎?+(𝑥) (5.7) 
Where the configuration parameter, 𝜂, scaled how much to weigh exploitation vs. 
exploration, the sequence 𝜅& was defined as: 
 𝜅& = 2 log \
𝑡2𝜋2
6 ^ (5.8) 
where 𝑡 was the number of samples. 
5.2.3.2 Bayesian optimization with learnable safety constraints 
To implment Bayesian optimization with learnable safety constraints, we extended 
the UCB acquisition function with the additional safety criteria designed to avoid 
stimulation settings expected to produce an average DS less than zero. When selecting a 
stimulation setting, the surrogate DS model was queried to identify regions of the 
parameter space that satisfied the criteria:  
 𝜇?E(𝑥) − 𝛽 ∗ 𝜎?E(𝑥) > 	0 (5.9) 
where 𝛽 was a configurable parameter to control how carefully the algorithm would avoid 
potentially unsafe regions of the parameter space. A high 𝛽 would cause the algorithm to 
avoid stimulation settings with even a small risk of producing a mean DS below zero. 
Wherease, a 𝛽 close or equal to zero, would cause the algorithm to only avoid regions of 





5.2.3.3 Bayesian optimization with hyperpriors 
The algorithm was further extended to incorporate information from prior subjects 
in the form of hyperpriors which could further improve the performance of the algorithm 
[45], [63]. When fitting the model by maximizing the likelihood over the space of 
hyperparameters defined in Chapter 5, Section 2.2, a prior distribution was placed on the 
hyperparameters. This distribution was calculated based on the ground-truth models for 
each other subject. The GP kernel used in this study has hyperparameters for the mean 
function, the length scale for the stimulation amplitude parameter, the signal noise, and the 
measurment noise. For each of the hyperparameters, the mean and variance across subjects 
was calculated and used to define a Gaussian distribution hyperprior for that 
hyperparameter. When fitting the model during optimization, the Gaussian distribution 
hyperprior was defined for each of the hyperparameters using these statistics. A 
configuration parameter, a, was multiplied the variance of the hyperprior, such that a small 
a would emphasize hyperparameters that are close to the hyperprior mean, while a large a 
would allow a broader range of hyperparameters to be considered. After each additional 
stimulation setting was tested, the model was re-fit using the hyperpriors and the entire 
parameter space re-estimated to compute the acquisition and safety functions form the 
surrogate model. 
5.2.4 Simulation experiments 
In silico experiments were performed using the ground-truth simulation models. In an 




optimization, Bayesian optimization with learnable safety constraints, Bayesian 
optimization with hyperpriors, and Bayesian optimization with learnable safety constraints 
and hyperpriors. The configuration parameters for the algorithms were selected to highlight 
the characteristic behaviors of the different optimization approaches.  
 In a second experiment, the configuration parameters for Bayesian optimization 
with learnable safety constraints and hyperpriors were more fully characterized. The 
configuration parameters were selected from uniform distributions of h (exploration) = [0 
4], b (safety) = [0 3], and a (hyperprior) = [0 3]. For each of the six subjects, the same 30 
combinations of configuration parameters were evaluated for 15 trials of 15 samples each.  
5.2.5 Algorithm performance criteria 
The algorithms were evaluated based on two criteria: final error and overshoot. 
Final error was calculated as the difference between the DA produced by the estimated 
optimal stimulation amplitude when applied to the ground-truth model and the max of the 
ground-truth model. The overshoot was calculated as the difference between the maximum 
stimulation amplitude and the estimated optimal stimulation amplitude. 
5.2.6 In vivo optimization  
5.2.6.1 Optimization phase 
Each optimization trial was initialized with a set of presumed safe stimulation 
settings:  ±0.0, 0.5, and 1.0 V. The DS was scored for each SOR task and used to fit the 




remained the same for three samples, or 30 samples total. During optimization, data from 
all trials were included, even if the subject did not interact with each object in the test phase 
of the SOR task. 
5.2.6.2 Validation phase 
In the validation phase, we prospectively randomized stimulation between ±0V/sham, the 
optimal stimulation setting estimated by the algorithm, x*, and a control point specified as 
the lower of either: 𝑥∗ + 1𝑉 or 2 ∙ 𝑥∗. If the control point did not produce a memory deficit 
in a given subject, an additional control point at 𝑥∗ + 2𝑉 was also evaluated. 
5.3 Results 
5.3.1 Data collection 
Stimulation and memory performance data was collected from six male Sprague 
Dawley rats between 16-50 weeks of age. The data from each subject included the 
stimulation amplitude and DS for the corresponding SOR task. Stimulation amplitudes 
included were based on a combination of previous optimization and system identification 
experiments. 
5.3.2 Ground truth models  
Ground-truth models were constructed using all available data for each of the six 
subjects. The stimulation amplitudes ranged from ±0-5 V, with two additional artificial 
data points at ±6 and 7 V (Figure 5.3). The estimated optimal stimulation amplitudes 




subjects, once the expectation of the simulation model crossed safety threshold it did not 
rise back above at higher stimulation amplitudes.  
 
Figure 5.3: Ground-truth simulation models. 
The simulation model mapping stimulation amplitude to the DS and the corresponding DA 
objective function. In the DS plot the green line shows the region of the ground-truth model 
where the expected DS is greater than 0, while the red portion of the line is when the 
expected DS is less than zero. The green and red circles show the data used to construct 
the ground-truth models when the DS measurement was above and below zero, 
respectively. The gray patch shows the standard deviation. In the DA plot, the solid and 
dashed lines indicate the expected DA based on the DS model and the standard deviation, 
respectively. The purple star indicates the estimated optimal of the DA objective function. 
5.3.3 Simulation experiments  
We first broadly characterized the behavior of the four different versions of the 
safe-opt algorithm in a representative subject (Figure 5.4). As expected, in both the 




selected simulation amplitudes at the high end of the parameter space that were below the 
safety threshold. When learnable safety constraints are employed, the search algorithm 
successfully avoided stimulation amplitudes above the safety threshold. However, when 
the hyperprior is not used, the search strategy is more conservative and does not fully 
explore the entire safe regions of the parameter space. When both components are 
employed, the search strategy fully explores the safe region of the parameter space without 
sampling from the unsafe regions. 
 
Figure 5.4: Component test.  
Simulated results using the four possible combinations of learnable safety constraints and 
hyperpriors on a representative subject model. The green and red lines represent the 
expected DS from the ground truth models for the safe and unsafe regions of the parameter 
space, respectively. Each circle represents the data collected during a simulated 
optimization trial. 
 The influence of configuration parameters on the performance of the full Bayesian 
optimization with learnable safety constraints and hyperpriors was then quantified (Figure 
5.5). The best, average, and worst performance of each of the 30 combinations of the three 
configuration parameters was compared on the ground-truth models. Across configurations 




the worst final error. However, the overshoot was sensitive to changes in the configuration 
settings, specifically b (Figure 5.5B). As b is increased, the average and worst case 
overshoot significantly decreases (p-value < 0.01), indicating a more conservative search 
strategy. The other two parameters, h and a were not significant predictors of either 
performance metric.  
 
Figure 5.5: Performance of META-SFE configuration parameters in silico.  
(A) The performance of each combination of configuration parameters in terms of final 
error and overshoot is represented by green, orange, and purple circles connected with 
black lines. (B) The overshoot of each combination of configuration parameters as a 
function of b. 
5.3.4 In vivo validation 
To validate our simulation experiments, standard Bayesian optimization was 
compared to the Bayesian optimization algorithm with learnable safety constraints and 




with the lowest final error and overshoot in the in silico prototyping were used. For the 
standard Bayesian optimization algorithm, h was set to 0.4 to be consistent with previous 
DS optimization experiments [37], [61]. 
5.3.4.1 Bayesian optimization for DA maximization 
In the first subject the stimulation amplitude parameter space was restricted to ±0-
5 V. After the first three burn-in samples at ±0, 0.5, and 1.0 V the algorithm immediately 
selected the stimulation amplitude of ±4.0 V, followed by limited samples at ±5.0 V before 
it ultimately converged to an estimated optimal stimulation amplitude of ±3.95 V (Figure 
5.6). In the validation phase, the DS at ±4.0 V was not significantly different than under 
sham conditions, and the DA at ±4.0 V was higher than at sham (DA=0, by construction; 
Figure 5.7). In a second subject, when the algorithm selected a stimulation amplitude of 
±4.0 V, the stimulation induced a Racine 5 behavioral seizure with rearing and falling. The 
fifth stimulation amplitude sampled by the algorithm, ±1.85 V also induced a seizure. 
Ultimately the algorithm converged on an estimated optimal of ±0.7 V, which was 





Figure 5.6: Optimization trajectory for DA maximization. 
Each column shows the optimization trajectory consisting of the input – voltage, the safety 
function – DS, and the objective function – DA. The red dashed line indicates the 
stimulation samples collected from the subject, while the thick black line indicates the 
estimate of the optimal stimulation amplitude and resulting DS and DA according to the 






Figure 5.7: Validation of Bayesian optimization for maximizing DA. 
(Top) The DS and DA under sham, optimal, and control stimulation amplitudes. Each 
circle represents a single trial, box plots indicate range and quartiles, gray line connects the 
mean from each condition. (Third row) GP model of the expected DS and confidence 
interval for a subject using all data collected over the study. The expectation of the model 
is shown with a green/red line indicating the safe/unsafe regions of the parameter space. 
Circles indicate samples collected during the optimization phase, colored green/red as 
inside or out of the safe region of the parameter space. Gray patch indicates the 95% 
confidence interval estimated from the GP. (Bottom) The DA objective function estimated 
from the model. Star indicates the optimum of the objective function. 
The META-SAFE algorithm designed in Chapter 5, Section 3.3 was then deployed in in 
vivo in two additional subjects. In both subjects, the selection of stimulation amplitudes to 
sample was much more conservative, with ±2.1 V as the highest amplitude sampled 




produced a negative DS, while for subject 5, the initial control point at ±2.1 V did not cause 
a memory deficit. However, an additional control stimulation at ±3.15 V did cause a slight 
decrease in performance. These findings indicate that the META-SAFE algorithm can 
more carefully avoid unsafe regions of the parameter space, but may not fully explore the 
entirety of the safe regions. 
 
Figure 5.8: Optimization trajectory for META-SAFE algorithm.  
Each column shows the optimization trajectory consisting of the input – voltage, the safety 
function – DS, and the objective function – DA. The green dashed line indicates the 
stimulation samples collected from the subject, while the thick black line indicates the 
estimate of the optimal stimulation amplitude and resulting DS and DA according to the 







































Figure 5.9: Validation of META-SAFE in vivo. 
(Top) The DS and DA (under sham, optimal, and control stimulation amplitudes. Each 
circle represents a single trial, box plots indicate range and quartiles, gray line connects the 
mean from each condition. (Third Row) GP model of the expected DS and confidence 
interval for a subject using all data collected over the study. The expectation of the model 
is shown with a green/red line indicating the safe/unsafe regions of the parameter space. 
Circles indicate samples collected during the optimization phase, colored green/red as 
inside or out of the safe region of the parameter space. Gray patch indicates the 95% 
confidence interval estimated from the GP. (Bottom) The DA objective function estimated 










In this study we designed and characterized a novel approach for safely optimizing 
brain stimulation. Using a previously described framework for designing and validating 
optimization algorithms for neural modulation we demonstrated how Bayesian 
optimization with learnable safety constraints can efficiently maximize a noisy objective 
function based on a memory task, while simultaneously avoiding regions of the parameter 
space that may disrupt memory.  
5.4.2 Interpretation of results 
The most evident challenge of this neural modulation optimization problem was the 
magnitude of the noise – the sample-to-sample variability – of this behavioral task. Across 
the models generated from the eight animals in this study, the average CNR was below 0.5, 
while in other studies, [35], [37], [63] the CNR of the objective function was closer 5.0. 
Based on this noisy objective and the extended time period to collect each sample (1/day) 
we restricted our analysis to Bayesian optimization based approaches. While the standard 
Bayesian optimization approach successfully identified optimal stimulation settings, the 
exploration mechanism of the algorithm led it to test the extremes of the parameter space, 
which ultimately resulted in side-effects for one of the subjects. 
In contrast, META-SAFE approach was able to slowly broaden the search space, 
avoiding extremes of the parameter space unless necessary to find the optimum of the 




convergence or overshoot. While we evaluated the effect of three different configuration 
parameters on the performance of the overall META-SAFE algorithm, only b, the 
parameter controlling the magnitude of the safety constraint, had a substantial effect on 
performance. By increasing b, we could limit by how much the stimulation amplitudes 
would overshoot the optimum with little effect on the other performance metric, final error. 
5.4.3 Related work 
Data-driven optimization approaches have been gaining traction for tuning brain 
stimulation in both clinical and pre-clinical studies. The foundational work applying data-
driven, particularly Bayesian, optimization to the field of neuroscience was in the context 
of designing the optimal audio-visual stimuli for an fMRI experiment [35]. Since, Bayesian 
optimization has been applied in silico for optimizing tACS stimulation [64], tuning a 
linear controller system for regulating subthalamic nucleus stimulation for PD [65], and 
for optimizing STN stimulation for multiple, mutually competitive objectives [63]. 
Additionally, it has been deployed in vivo for modulating hippocampal gamma (32-50 Hz) 
power with optogenetic stimulation of the medial septum [37]. While the approaches have 
been found to be effective, only the multi-objective optimization algorithm accounted for 
side-effects, but lacked a mechanism for avoiding side-effects or unsafe regions of the 
parameter space. In the approach presented here, the algorithm actively learns a surrogate 






5.4.4 Future work 
While we explored one possible implementation of Bayesian optimization with 
learnable safety constraints, safe optimization is a nascent field with ongoing advances in 
the algorithms [58], [66]. In particular, these safe-optimization approaches can leverage 
surrogate models more appropriate for high-dimensional parameter spaces [67] to 
accommodate more complex stimulation settings. The mechanisms for learnable safety 
constraints can also be incorporated into multi-objective  and state-dependent optimization 
[48] optimization problems. Ultimately, all of these approaches will be critical for 
developing safe and effective automatic optimization approaches for neural modulation. 
5.4.5 Limitations of the study 
The results of this study should be interpreted based on the overall goal of designing 
a safe optimization algorithm using a proof-of-concept model system. While asynchronous 
distributed stimulation is a potential therapeutic option for drug-resistant temporal lobe 
epilepsy, and it will be crucial to consider any memory side-effects, this study was not 
designed to provide insight into the clinical or cognitive effects of the therapy. The 
algorithm designed for safely maximizing DA is specific to this particular optimization 
problem. However, these results show that the overall framework can be used to design 
problem-specific safe optimization algorithms – even for very noisy behavior-based 







Bayesian optimization with learnable safety constraints can safely and efficiently 
identify stimulation settings that maximize a noisy behavior-based objective function while 
avoiding regions of the parameter space that may be unsafe. 
5.5 Supplement 
5.5.1 Maximization and minimization of DS 
Bayesian optimization with objective function of maximization of memory was 
able to sufficiently characterize the memory performance in 13 iterations for Rat 2 and 11 
iterations for Rat 1 and Rat 3 (Figure 5.10). Bayesian optimization with objective function 
of minimization of memory was able to sufficiently characterize the memory performance 
in 14 iterations for Rat 1, 11 iterations for Rat 2, and 12 iterations for Rat 3 (Figure 9). 
There were no specified convergence criteria, as heretofore insufficient data had been 
collected. Visualizing the approximation of the objective function learned by the Bayesian 
optimization algorithm, it can be shown that each rat responded differently to the 
stimulation. Rat 1 showed memory impairments from any stimulation over 0 V. Rat 2 was 
able to tolerate voltages up to 1 V before showing memory impairments. Rat 3 was able to 
tolerate voltages up to 1.5 V before showing considerable memory impairments. Figure 
5.11 makes it clear that increasing voltage stimulation did not result into an aversive 





Figure 5.10: The BaO algorithm with the objective function of maximization of 
memory. 
(A-C) Memory performance with increasing voltage stimulation for Rats 1-3, respectively. 
Stimulation frequency was set at 7Hz. Red dotted line indicates a threshold score, 
performance above which demonstrates memory. Spatial object recognition task was used 
to test memory in normal rats during active ADMES stimulation. The shaded area indicates 
the confidence interval of the GP model. 
 
 
Figure 5.11: The BaO algorithm with the objective function of minimization of 
memory. 
(A-C) Memory performance with increasing voltage stimulation for Rats 1-3, respectively. 
Stimulation frequency was set at 7Hz. Red dotted line indicates a threshold score, 
performance above which demonstrates memory. Spatial object recognition task was used 
to test memory in normal rats during active ADMES stimulation. The shaded area indicates 





CHAPTER 6. APPLICATION OF THE FRAMEWORK FOR 
MULTIPLE OBJECTIVES  
6.1 Introduction 
6.1.1 DBS for PD 
As described in Chapter 1, Section 1.1, a common example of DBS is electrical 
stimulation of the subthalamic nucleus (STN) for the treatment of motor symptoms (e.g. 
tremor, bradykinesia) in PD [1], [16], [68], [69]. A major challenge for the therapy is 
finding a setting that stimulates the STN region to maximally reduce motor symptoms, 
while avoiding the corticospinal/bulbar tract in the internal capsule – a neighboring white 
matter pathway – which can induce involuntary muscle contractions, speech problems, or 
pain [55], [70]. The current standard of care is to apply different stimulation settings in 
clinic and observe the patient’s clinical signs and feedback regarding side effects, which 
can be subjective and time-consuming [12], [13], [70]. To address this problem, there is 
active research into electrophysiological and kinematic biomarkers that may be used to 
rapidly and quantitatively evaluate the effectiveness of a stimulation setting [17], [27], 
[71]–[75]. Cortical (cEP) and motor (mEP) evoked potentials have been investigated as 
putative biomarkers for stimulation effectiveness (activation of cortico-subthalamic 
hyperdirect pathway) and motor side effects (activation of corticospinal/bulbar tract), 
respectively [76]–[79]. While the cEP and mEP measures have not yet been prospectively 




between symptom control and side effects, and can be used as a model system for 
developing novel approaches for DBS programming. 
6.1.2 Multi-objective optimization for DBS programming in PD 
One approach is to frame DBS programming as a multi-objective optimization 
problem, for which many potential engineering solutions exist [80], [81]. From this 
perspective, the goal of DBS programming is to simultaneously address multiple, often 
mutually competitive, objectives – controlling symptoms while minimizing side effects. 
The optimal trade-off between the objectives is referred to as the Pareto set (Figure 6.1). 
In the context of DBS programming, the Pareto set would be the subset of stimulation 
settings that are superior to all others in at least one of the symptom or side effect 
objectives. In contrast, the stimulation settings not in the Pareto set are those that are 
inferior to at least one other stimulation setting on all objectives. The goal of a multi-
objective optimization algorithm in this study is therefore to accurately identify which 
stimulation settings are in the Pareto set – a substantially smaller subset of the overall 
parameter space. This could reduce the size of the parameter space that needs to be 
evaluated clinically, and in turn may accelerate DBS programming and allow for more 
effective stimulation settings to be identified. Rather than viewing this optimization 
approach as a method to determine one optimal setting, calculating the Pareto set allows 
flexibility to consider competing demands (e.g., changing the level of acceptable side 






Figure 6.1: Pareto set as the optimal trade-off between symptom relief and side-
effects. 
Each circle represents the effect of a single stimulation setting on both symptom relief and 
side effects. The Pareto set are those stimulation settings farthest to the right (maximizing 
symptom relief) and bottom (minimizing side-effects) shown in dark green. In addition to 
the optimal trade-off, all other stimulation settings can be ranked in terms of favorability 
with the Pareto set having a rank of 0. In this example, the light green points have a worse 





6.1.3 Extension of framework for multiple objectives  
In this study, we extended a previously described framework for designing data-
driven optimization systems for neural modulation [37]. Originally developed for single 
objectives, we adapted this framework to the multi-objective optimization of the cEP and 
mEP neural features (Figure 6.2). Following this framework, we used intraoperative cEP 
and mEP data to construct a set of statistical ground-truth models that captured the response 
of these features to STN stimulation for each patient. We then performed simulation 
experiments in which we sampled from these models for high-throughput prototyping of 
different multi-objective data-driven algorithms, to identify the algorithmic components 
necessary for successful optimization. While the resultant design information is specific to 
the putative cEP and mEP neural features, the overall framework can be readily adapted to 





Figure 6.2: Framework for designing multi-objective optimization algorithms for 
STN DBS. 
Clockwise from top left. During the procedure to implant the DBS device, the clinical 
electrode is used to stimulate the STN while ECoG and EMG are being recorded as raw 
data. The raw data is filtered and the cEP and mEP electrophysiological features are 
annotated. These features, the measured data, are then combined with augmented data to 
fill in missing data points and approximate higher dimensional parameter spaces (e.g. the 
effect of pulse-width). The measured data and the augmented data are then fit to a Gaussian 
process model to represent the input -> output (stimulation parameters ->  cEP/mEP) 
relationships derived from an individual subject. These models allow for interpolated data 
to be estimated for stimulation settings that were not applied in the intraoperative 
experiments. These models are then used for high-throughput prototyping of different 
algorithms on the task of identifying the optimal trade-off between the two objectives – 
maximizing cEP and minimizing mEP – known as the Pareto set. Since Gaussian processes 
naturally estimate the mean and variance of the output, they can generate noisy simulated 
data that can be used to evaluate the performance of data-driven optimization algorithms 
in a realistic context. Each algorithm is evaluated in terms of its accuracy (AUC) and rate 
at which it identifies the Pareto set. Finally, the algorithm that performs best will be well-
poised for deployment in vivo in future studies. 
6.2 Methods 
The organization of the methods follows the two key steps in the design framework: 
1) data collection and modeling, and 2) high-throughput prototyping of different 
algorithms. Section 6.2.1 describes how the dataset used in this study was collected, how 
it was processed, and how our cEP and mEP neural features were obtained. Then, section 
6.2.2 uses this data to construct ground-truth statistical models for each subject for the 
purpose of testing a range of optimization approaches in silico. Section 6.2.3 formally 
defines the solution to a multi-objective optimization problem, the Pareto set, and how it 
was calculated. Section 6.2.4 details a set of optimization algorithms chosen to highlight 
particular characteristics of multi-objective optimization approaches. Finally, section 6.2.5 
defines performance metrics specific to this clinical context that were used to compare the 




6.2.1 Data collection 
6.2.1.1 Electrode implantation and biomarker recordings 
Subjects included in this study were undergoing surgery to implant electrodes in 
the STN as part of the standard of care for treatment of medically refractory PD. As part of 
an additional research study, a 28-contact subdural ECoG recording strip (Ad-Tech) was 
temporarily placed over the motor cortex ipsilateral to the stimulating electrode. Activity 
of up to 8 contralateral muscles were recorded with surface EMG electrodes. The relevant 
experimental methods are summarized below, but additional details describing the protocol 
can be found in a prior publication where data from patients 1 and 2 were presented [76]. 
This study was approved by the Emory University Institutional Review Board. 
6.2.1.2 Grid search experiments 
The raw data were collected by applying stimulation via the clinical lead in the 
STN while simultaneously recording from the ECoG and EMG electrodes. A parameter 
sweep was performed where a pre-specified set of stimulation settings was applied. Each 
stimulation setting consisted of a different combination of current amplitude, active 
(negative or cathode) contact, and return (positive or anode) contact. The order of the 
stimulation settings was randomized, and sequentially applied for 12 seconds followed by 
a 3 second pause before the next stimulation. Stimulation pulse width was set to 60 µs and 
stimulation frequency to 10 Hz. Stimulation could be monopolar – where a contact on the 
electrode is used as the cathode and a shoulder patch is used as a remote return/anode, or 




DBS lead model was Medtronic 3389 for subjects 1-4 and Abbott 6172 for Subject 5. All 
subjects had each monopolar configuration tested at 1, 3, and 5 mA (pseudo-ring settings 
were used for the segmented electrode in subject 5). Subsets of bipolar configurations were 
tested at the same amplitudes, although some combinations of configurations and 
amplitudes were not tested in some subjects. Specific data used are detailed in Table 6.1. 
6.2.1.3 Measuring cortical and motor evoked potentials  
ECoG and EMG signals were recorded at a 22 kHz sampling rate using a Neuro 
Omega data acquisition system (Alpha Omega Engineering). ECoG was re-referenced with 
a bipolar montage between adjacent contacts along the recording strip to create 26 bipolar 
recording channels. Stimulation pulse onset was automatically detected from the ECoG or 
EMG channel with the largest stimulation artifact. Segments were time-aligned on pulse 
onset, averaged to resolve the evoked potential, and peak/trough amplitudes and latencies 
were visually determined. The amplitude of the evoked potential between 2-4 ms was 
measured for each bipolar ECoG channel as the cEP, indicating the degree of antidromic 
cortico-subthalamic hyperdirect pathway activation. The maximum amplitude of cEP 
across ECoG channels was used as the putative biomarker of therapeutic benefit. 
The mEPs were manually annotated as the signal peak for each EMG channel. 
Signals where no clear peak was visible at the expected latency were annotated as 0 µV. 
The sum amplitude of the mEP across the available EMG channels was used as a biomarker 





6.2.1.4 Data augmentation 
For some subjects, data were not collected for stimulation settings on the borders 
of the bipolar parameter space (3+/0- and 0+/3-). As the statistical models used to represent 
the data, described in Chapter 6, Section 2.2, are better suited to interpolation rather than 
extrapolation, the initial ground-truth model estimates in these regions of the parameter 
space were not physiologically appropriate. To compensate for this, artificial data points 
were manually added to the ground-truth models in the form of augmented data. (Table 
6.1). These data points had inputs corresponding to the missing stimulation setting and 
outputs were proportional to those of the patients with complete data, where the wide 
bipolar setting has a similar, but smaller effect than for the monopolar setting at the same 
contact and amplitude. 
While there were not enough data to directly model the effect of different pulse 
widths on the two objectives, limited experiments applying stimulation at 20, 60, and 120 
µs indicated a sigmoidal increase in cEP with increasing pulse width (Figure 7C in [84]). 
To incorporate pulse width, the bipolar ground-truth models were augmented with data 
created by passing known cEP and mEP values through a sigmoid function. These data 
augmentation steps may have produced ground-truth models that were less consistent with 
the original specific subjects. However, the intention was to capture the appropriate 
characteristics and diversity to suitably measure the performance of potential optimization 





6.2.2 Constructing ground-truth models for simulation 
The data from the intraoperative experiments were then used to construct 
simulation models for each subject. The goal of these models was to allow an optimization 
algorithm to interact with a black-box function that, for a given set of stimulation 
parameters, would produce a stochastic response consistent with previous experiments. 
These models represented ‘known’ ground-truths corresponding to individual subjects that 
provided realistic conditions to prototype and evaluate a data-driven optimization 
algorithm. 
6.2.2.1 Spatial organization of stimulation parameters 
The first step to construct the ground-truth models was to determine the 
organization of the parameter space (Figure 6.3). Monopolar stimulation was modeled as 
a two-dimensional parameter space consisting of the four cathodes and 50 pulse amplitudes 
ranging from 0.1 mA to 5.0 mA with an increment of 0.1 mA, similar to the increments 
used in DBS programming [12]. All combinations of cathode and amplitude created a 
parameter space with a total of 200 potential stimulation settings (Figure 6.3a). This 
monopolar (2D) parameter space produced two surfaces for the cEP and mEP biomarkers 
(Figure 6.3b,c). Bipolar stimulation was modeled as a three-dimensional parameter space 
consisting of 16 cathode/anode pairs and 50 pulse amplitudes, for a total of 800 potential 
stimulation settings (Figure 6.3e). Monopolar configurations were also included in the 
bipolar model and assigned to the coordinates where cathode and anode are the same 




parameter space, surfaces were constructed for multiple amplitude cross-sections (Figure 
6.3f). A four-dimensional parameter space – bipolar/pulse width (4D) – was modeled using 
the bipolar stimulation model with an additional 6 pulse widths (20 µs to 120 µs with 20 
µs increments), for a total of 4,800 potential stimulation settings. The bipolar/pulse width 
models were visualized using multiple bipolar models, each a three dimensional cross-










(a) Spatial arrangement of the monopolar (2D) model. (b and c) Ground truth models for 
cEP and  mEP, respectively, for Subject 1. Surface is the expectation of the Gaussian 
process model. Color gradient is for visualization. (d) The objective space for the ground 
truth model. Colors correspond to the monopolar cathode used for stimulation (as shown 
in 2a), estimated at 50 different amplitudes indicated by the transparency of the circle, 
where 5 mA is fully opaque. (e) Spatial arrangement of the bipolar (3D) model. (f) Ground-
truth model of bipolar stimulation. The surfaces represent a cross section of the model at 
1, 3, and 5 mA. (g) Spatial arrangement of the bipolar/pulse width (4D) model. (h) Bipolar 
cross-sections of a ground-truth model at 20, 60, and 120 µs.  
6.2.2.2 Model fitting 
Each ground-truth model consisted of two Gaussian processes (GP) models that 
estimated cEP and mEP outputs for a given stimulation setting [45]. A Gaussian process is 
composed of a mean function:   
 µ	 = 	m(𝐱!) (6.1) 
and a covariance function: 
 Σ = 	k(𝐱, 𝐱!) (6.2) 
where 𝐱 is a vector containing the data used to construct the model, and 𝐱! is the sample 
point. In our application, the inputs to the model were restricted to those detailed in Chapter 
2 Section 2.2. The output was the cEP and mEP drawn from Gaussian distributions:  




In our implementation, we used a GP with a constant function based on the mean 
of the data, and a third order Matérn kernel with automatic relevance determination for the 
covariance: 
 𝑘4𝑥/ , 𝑥09 = 𝜎1241 + √3𝑟9 exp4−√3𝑟9 (6.4) 
where 𝜎12 is the variance of observation and:  







where 𝜎$2  is the set of length scale hyperparameters which describe the variance of 𝑥$, 
[45]. In other words,	𝜎$2  represents how much the expectation can vary only a given 
dimension of the parameter space. Each model was individually reviewed and model 
hyperparameters (mean, length scale, signal noise, measurement noise) were manually 
adjusted in the event of overfitting or non-physiological responses.  
6.2.2.3 Simulation Model 
After fitting the ground-truth cEP and mEP models, they were wrapped in a 
simulation function to replicate the noise or stochasticity inherent to any biological system. 
For a feasible stimulation setting defined in 6.2.2.2., the simulation function calculates the 




are drawn from a normal distribution with 𝜇 and 𝜎	to output an appropriately stochastic 
response to stimulation . 
6.2.3 Estimating the Pareto Rank 
The goal of multi-objective optimization is to identify the Pareto set. In the context 
of DBS programming, the Pareto set is defined as set of stimulation settings that are non-
dominated. A stimulation setting is non-dominated if there is no other stimulation setting 
that can improve on one objective (e.g. increasing cEP) without worsening on another 
objective (e.g. increasing mEP) (Figure 6.1). 
Mathematically [85], for a system 𝑓:ℝK → ℝ$, where 𝑋 is a set of feasible inputs 
on ℝK, and 𝑌 is the feasible set of objectives in ℝ$, such that: 
 𝑌 = {𝑦	 ∈ ℝ$ ∶ 	𝑦 = 𝑓(𝑥), 𝑥 ∈ 𝑋} (6.6) 
A point 𝑦!!∈ℝ( strictly dominates another point 𝑦!∈ℝ(, if 𝑦!! is superior to 𝑦! on all 
objectives, written as 𝑦!! ≻ 𝑦!. Therefore, the Pareto set 𝑃(𝑌) is defined as: 
 𝑃(𝑌) = {𝑦! ∈ 𝑌 ∶ 	 {𝑦!! ∈ 𝑌 ∶ 𝑦!! ≻ 𝑦!, 𝑦! ≠ 𝑦!!} = Ø} (6.7) 
While inclusion in the Pareto set is binary, a relative Pareto rank can be calculated 
recursively [86]. The recursive dominance order ranks stimulation settings by first 
calculating the Pareto set, assigning it a rank of 0, then removing it. The Pareto set is then 




settings are left. Therefore, a stimulation setting with rank 0 would be in the Pareto set, and 
settings with better ranks (lower numbers) would be close to the Pareto set and nearly 
optimal, while settings with worse ranks (higher numbers) would be less optimal. The 
Pareto rankings were then used to label all the stimulation settings in the parameter space 
on a gradient where a cut-off could be specified for what is considered clinically relevant 
(Figure 6.4). Increasing the cut-off would cause a larger parameter space to be labeled as 
a member of the Pareto set (less specific), but more likely to include the true optimal for a 
given subject (more sensitive). We specified this cut-off based on the minimum ranking 
necessary to include the stimulation found to be optimal through traditional DBS 
programming. 
The Pareto ranking for the ground-truth cEP and mEP models was calculated across 
each potential stimulation setting to create a known solution to the multi-objective 
optimization problem. Therefore, the goal of the optimization algorithm was to correctly 
estimate the Pareto ranking for all stimulation settings while testing as few settings as 
possible. We evaluated three different approaches for estimating the Pareto ranking as 







Figure 6.4: Mapping from parameter space to objective space to estimate Pareto 
rank. 
Left, The set of feasible stimulation settings in the monopolar parameter space. The top 3 
Pareto ranks are highlighted as Pareto set (dark green), rank 1 (green), and rank 2 (light 
green). Stimulation settings with a Pareto rank greater than 2 are open grey boxes. Middle, 
The cEP and mEP ground-truth models for Subject 1. Surface is the expected output for a 
given stimulation setting. Data points used to fit model are black dots. Right, The objective 
space. Each circle corresponds to a specific stimulation setting and is color coded by Pareto 
rank as in the parameter space. 
6.2.3.1 Pareto set based on measured data 
In the simplest approach, the optimization algorithm calculated the Pareto set using 
the actual noisy measured data. Within the parameter space defined in Chapter 6, Section 
2.2, the Pareto ranking was calculated for stimulation settings that were actually tested. All 
other untested stimulation settings were then assigned to one Pareto rank worse/higher than 






6.2.3.2 Pareto set based on surrogate model data 
In a second approach, the optimization algorithm estimated the effect of all the 
stimulation settings, tested and untested, using a surrogate model. A surrogate model is a 
typically statistical model that is fit to the limited stimulation/measurement data collected 
during the optimization process. Two GPs, as described in section Chapter 6, Section 2.2.1, 
were used as surrogate models to estimate how each stimulation setting in the parameter 
space would affect the cEP and mEP. While the surrogate models used the same statistical 
structure as the ground-truth models, they were only fit to the noisy data collected during 
the optimization process, and had no prior information on the ground-truth Pareto ranking. 
After each additional stimulation setting wis tested on the ground-truth models, the data 
were added to the models, the hyperparameters were re-fit, the entire parameter space was 
re-estimated, and each stimulation setting is assigned an estimated Pareto rank. 
6.2.3.3 Hyperpriors 
In a third approach for estimating the Pareto set, information from other subjects – 
in the form of hyperpriors – was incorporated when fitting the surrogate models, which 
could improve the estimate of the parameter space and the accuracy of the Pareto ranking. 
Hyperpriors are used to specify a prior distribution for the hyperparameters in a GP model. 
For example, if a stimulation setting has a relatively small effect in four subjects, but a very 
large effect when first tested in a fifth subject, the hyperprior will help attribute that data 
point to noise, rather than reliable data [41]. This can be especially useful when little data 




study, hyperpriors were not used when constructing the ground-truth models, but were 
evaluated as a potential component of the optimization algorithms (Chapter 6, Section 2.4) 
The hyperpriors for a given subject were created using the model hyperparameters 
from all other subjects. The Gaussian process kernel used in this study has hyperparameters 
for the mean function, the length scales, the signal noise, and the measurement noise that 
are selected during model fitting and are going to be specific to each subject model. To the 
construct a hyperprior for a given subject, the hyperparameter values were taken from all 
other models and the mean and standard deviation were calculated for each one, 
representing a prior Gaussian distribution of those hyperparameters. When fitting the 
model during optimization, the Gaussian distribution hyperprior was defined for each of 
the hyperparameters using these statistics. After each additional stimulation setting was 
tested on the ground-truth models, the model was re-fit using the hyperpriors, the entire 
parameter space re-estimated, and Pareto ranks assigned to each possible stimulation 
setting. 
6.2.4 Multi-objective surrogate-model optimization 
There is no established approach for efficiently sampling stimulation settings for 
programming STN DBS or other neural modulation applications, although some protocols 
and heuristics have been described [12], [13]. As such, we sought to broadly compare 
sampling strategies that represented different classes of algorithms. Following the 
framework, ground-truth models wrapped in the simulation function were used to 




samples from a fixed grid, a simple surrogate-model evolutionary approach, random 
sampling, and Bayesian optimization with an expected hypervolume improvement (EHVI) 
acquisition function. 
6.2.4.1 Fixed Grid  
Ten stimulation settings were randomly selected from the parameter space based 
on a uniform distribution without replacement. Each stimulation setting was sampled 10 
times in a random order. While 10 samples of the same stimulation setting may not be 
necessary in practice, this allowed for an equitable comparison to the other search strategies 
with 100 samples. After each sample, the Pareto ranks were assigned using the three 
approaches defined in Chapter 6, Sections 2.3.1-2.3.3: 1) the noisy simulated cEP and mEP 
data, 2) the entire input space estimated using surrogate models fit to the simulated data, 
and 3) fitting the GP models to the simulated data using hyperpriors derived from all other 
subject models.  
6.2.4.2 Evolutionary search 
In the initial iteration, 10 stimulation settings were randomly selected from the 
parameter space based on a uniform distribution and then applied to the ground-truth 
model. The simulated data were fit to surrogate GP models and used to estimate the entire 
parameter space. The 10 stimulation settings with the best/lowest Pareto ranking were then 
sampled, and Pareto rankings iteratively recalculated. This process was repeated for 10 
iterations or a total of 100 samples. Separate experiments were performed with and without 




6.2.4.3 Random sampling 
One hundred inputs were randomly and uniformly selected with replacement from 
the parameter space. The Pareto set was then calculated using the three approaches 
described in Fixed Grid. 
6.2.4.4 Bayesian optimization with expected hypervolume improvement acquisition 
function  
As part of an initial burn-in period, 10 stimulation settings were randomly selected 
from the parameter space based on a uniform distribution and applied to the ground-truth 
model. The burn-in samples were then fit to surrogate GP models for cEP and mEP. The 
EHVI acquisition function was then used to select the sample point. This was repeated for 
a total of 100 samples. Separate experiments were performed as in the evolutionary search. 
The goal of the EHVI acquisition function is to identify the stimulation setting 
expected to provide the largest increase in the hypervolume created by the estimated Pareto 
set [87]. For a candidate stimulation setting, the expectation 𝜇 and uncertainty 𝜎 were 
estimated from the cEP and mEP surrogate models constructed from the simulated data. 
Two new models, cEP* and mEP*, were then created by adding an additional datapoint 
consisting of the candidate stimulation setting, and the “best-case” outputs defined as 
𝜇-75 + 𝜅 ∙ 𝜎-75 and 𝜇$75 + 𝜅 ∙ 𝜎$75, where 𝜅 is a configurable parameter within the 
algorithm. The Pareto set was then estimated based on the cEP* and mEP* models and the 




stimulation setting that predicted the largest EHVI was found using a standard single-
objective Bayesian optimization approach [44]. 
6.2.5 Performance metrics 
After prototyping the different data-driven multi-objective optimization algorithms 
on the ground-truth models, the performance of the algorithms was quantified and 
compared.  
6.2.5.1 Pareto AUC 
The performance of the optimization algorithm was computed using the area under 
the receiver operating characteristic curve (AUC). To do this, we framed the comparison 
between the Pareto set estimated by the optimization algorithm and the ground-truth 
reference Pareto set as a classification problem. To adjust the sensitivity vs. specificity, the 
Pareto ranking threshold (Chapter 6, Section 2.3) for inclusion in the Pareto set could be 
relaxed. For example, if the threshold was set to only compare those stimulation settings 
with Pareto ranking equal to zero, the classifier would have perfect specificity, but no 
sensitivity. In contrast, if the threshold was set to include all stimulation settings, the 
classifier would have perfect sensitivity, but no specificity. By sweeping the Pareto rank 
threshold from highest specificity to highest sensitivity, the receiver operating 
characteristic curve was calculated to produce the AUC. The AUC was used as the primary 





6.2.5.2 Convergence rate 
To measure the convergence rate, the AUC was calculated after each sample was collected. 
The AUC was then fit to an exponential loss model as a function of sample,  
 𝐴 ∗ 𝑒B>& (6.8) 
The coefficient b was then used as the measure for convergence rate. More negative 
indicated faster progression towards a high AUC 
6.2.6 Analysis and statistics 
A single 5-way analysis of variance (ANOVA) model with post-hoc comparison 
using Tukey’s procedure was constructed using the final AUC and convergence across 
search strategy, modeling approach, dimensionality of the parameter space, subject, and 
trial. The relevant aspects of this ANOVA model are described in Chapter 6, Sections 3.3.1 
and 3.3.2 and the full list of p-values for each predictor and interaction is shown in Table 
6.2.  
In Chapter 6, 3.3.3, linear regression is used to determine whether varying the 
configuration parameters of the EHVI+Model and EHVI+Hyperprior significantly affect 





P-values are reported; however, given the high-throughput nature of these 
simulation experiments, large numbers of repeated simulation trials can lead to arbitrarily 
low p-values. 
Unless otherwise noted, simulation experiments were performed for each subject 
using 30 independent optimization trials consisting of 100 samples. All simulations and 
analysis were implemented using Matlab 2020a (Mathworks, Natick, MA) and performed 
on a desktop computer with an Intel i7 8th generation 8-core 3.60 GHz processor and 64 
GB of DDR3 RAM. 
6.3 Results 
Electrophysiology data (cEP and mEP amplitudes at different stimulation settings) 
from 5 patients with PD were used in this analysis. The data set included complete 
monopolar parameter sweeps (4 contacts, 3 amplitudes each) for all subjects, and a 
sufficiently complete bipolar parameter sweep (10-12 contact configurations, 0-3 
amplitudes each) for 4 of the subjects. The bipolar data for subjects 1 and 4 were augmented 
with 2 and 3 additional data points, respectively (Table 6.1) and all data points were 
replicated for each subject at pulse widths 20 µs and 120 µs to create the bipolar/pulse 







Table 6.1: Subject characteristics and collected data. 
Subject Age/Sex DBS lead 
model 
Cortical strip side/ 









1  62/M Medtronic 
3389 












3 mA at  
0+3-, 3+0- 
 
All at  
20 µs and 120µs 
2  65/M Medtronic 
3389 











3 mA at  
0+3-,3+0- 
 
All at  
20 µs and 120µs 
3 53/M Medtronic 
3389 











All at  
20 µs and 120µs 
4 57/M Medtronic 
3389 











1,3,5 mA at 
0+3- 
 
All at  
20 µs and 120µs 
5 44/M Abbott 
6172 





6.3.1 Clinical interpretation of the Pareto ranking 
We first used the electrophysiology data to build ground-truth models for individual 
subjects as described in Chapter 6, Section 2.2. For two subjects (4 and 5) we were able to 
visualize clinically optimized stimulation settings (determined by the clinician using a 
standard clinical approach) in relation to the Pareto set obtained from the subject-specific 
ground-truth monopolar (2D) models. A similar comparison could not be made for the 
remaining 3 subjects because one used a wide bipolar setting and one used double 




subjects and so could not be accounted for in the models. For the third subject we did not 
have access to clinical programming data. 
Both subjects had clinical stimulation settings with a C+/1- contact configuration 
and 60 µs pulse width, but at different amplitudes (3.6 mA and 2.25 mA, respectively). By 
estimating the Pareto Rank for the entire monopolar parameter space, we found that the 
monopolar stimulation setting selected by the clinician was contained within the first three 
Pareto ranks for subjects 4 and 5, representing 31% and 58% of the total parameter space, 
respectively (Figure 6.5). Across all subjects, the first three Pareto ranks represented a 





Figure 6.5: Clinical stimulation settings compared to the Pareto ranking from the 
ground-truth models. 
(a) Subject 4, (b) Subject 5. Red circle represents the clinical stimulation setting. (i) the 
monopolar stimulation parameter space where the stimulation settings within the three 
lowest/best Pareto rankings are filled, and the stimulation settings with Pareto rankings 
higher/worse than three are left empty. (ii) The ground-truth models fit to the measured 
data (black dots). (iii) the objective space with the three highest/best Pareto rankings filled.  
6.3.2 Multi-objective optimization for learning the pareto set 
Next, we utilized the subject-specific ground truth models to assess performance of 
different optimization algorithms in their ability to accurately and efficiently estimate the 
Pareto ranking. To visualize the optimization process, we first present a representative 
example of the search trajectory at three different time points when optimizing over a 
monopolar (2D) parameter space (Figure 6.6). When only 5 samples (stimulation settings) 
are collected (Figure 6.6, Left column), there is a substantial mismatch between the two 
estimated models and the ground-truth, particularly the difference in the cEP and mEP 
magnitudes. This can be seen in the surrogate models fit to the simulated data (Figure 6.6, 
Top two rows) and in the estimated objective space (Figure 6.6, Third row). As a result, 
there is also a substantial mismatch between the Pareto ranking estimated using the 
surrogate models and the known ground-truth Pareto set (Figure 6.6, Bottom row). 
As additional samples are collected (Figure 6.6, Middle and right columns), the 
surrogate models begin to better approximate the ground-truth. As a result, the Pareto 






Figure 6.6: Search trajectory for EHVI+Model on a monopolar (2D) model. 
Ground-truth model from Subject 1. Each column shows the state of the optimization 
algorithm after a certain number of samples have been collected. Top two rows, The 
surrogate cEP and mEP models constructed from the simulated data (black dots). Third 
row, The objective space estimated from the cEP and mEP models. Each circle corresponds 
to a stimulation setting from the full parameter space estimated with the cEP and mEP 
surrogate models. The filled green circles are those stimulation settings within the first 
three Pareto rankings estimated from the surrogate models. The black dots indicate the 
Pareto set calculated from the ground-truth models. Bottom row, The parameter space 




6.3.3 Algorithm behaviour and performance 
6.3.3.1 Algorithm component test 
While the 10 combinations of search strategy and modeling approaches were 
evaluated for all three model parameter spaces – monopolar (2D), bipolar (3D), 
bipolar/pulse width (4D) – we first compare their performance on the bipolar (3D) models 
as they represent a common clinical scenario. Overall, the selection of both the search 
strategy and modeling approaches were significant predictors of performance in terms of 
final accuracy (search strategy: p-value = 7.9e-230; modeling approach: p-value = 0) and 
convergence rate (p-value = 2.4e-40 and p-value = 4.6e-66, respectively; Figure 6.7a). 
Between algorithms, those using the EHVI search strategy performed best in terms of final 
AUC and convergence rate. Next was the random search, which outperformed the 
evolutionary search strategy despite it using the surrogate model to guide sampling. The 
grid search strategy performed the worst. Between the two algorithms that could be used 
with or without a model, Grid and Random, the use of the surrogate model was critical to 
performing above chance (AUC > 0.50). The inclusion of a hyperprior did not improve 
performance for these search strategies, despite providing additional a priori information. 
On a per-sample basis (Figure 6.7b), the performance trajectory for EHVI+Hyperprior was 
better as early as 25 samples into the optimization and had a smaller variance across the 30 
independent trials, when compared to the other search strategies combined with model 
hyperpriors. In the 5-way ANOVA model, trial was not a significant predictor of final AUC 





Figure 6.7: Comparison of algorithms on the bipolar (3D) parameter space. 
(a) Final AUC and convergence for the 10 algorithm combinations. X-axis is reversed for 
the convergence rate as more negative values are preferable. Error bars indicate 
uncorrected 95% CI. (b) AUC trajectory measured at each sample. Patches indicate the 
standard error. Dashed line shows the chance threshold for AUC = 0.5. Performance for 


















Table 6.2: Significance of predictors in 5-way ANOVA model. 


















dimension x subject 6.83E-43 
 
7.71E-25 
dimension x model 8.25E-147 
 
2.44E-10 
dimension x search 7.19E-28 
 
3.98E-11 
dimension x trial 5.10E-02 
 
4.33E-01 
subject x model 5.23E-37 
 
1.18E-12 
subject x search 3.05E-06 
 
1.38E-06 
subject x trial 9.28E-01 
 
1.86E-01 
model x search 3.95E-113 
 
4.90E-22 
model x trial 5.74E-01 
 
2.80E-01 
search x trial 4.24E-02 
 
9.47E-01 
Values below 0.05 are bolded.  
a dimensionality of the parameter space coded [0-2] 
b subject data used to construct the model coded [0-3] 
c modeling approach coded [0-2]  
d search strategy coded [0-3] 
e Trial number coded [0-29] 
*p-value below MATLAB machine precision. 
 
6.3.3.2 Parameter space dimension  
After evaluating all algorithms on the bipolar (3D) ground-truth models, we 
compared the Hyperprior versions of each search strategy and characterized their 




ground-truth models (Figure 6.8). We found that, in addition to search strategy, the 
parameter space dimensionality was a significant predictor of both final AUC (p-value = 
2.33e-306) and convergence (p-value = 2.08e-20). As the dimensionality of the parameter 
space increased there was a general decrease in the final AUC achieved by each algorithm. 
However, this decrease was not uniform. The EHVI+Hyperprior algorithm showed no 
decrease in performance from 2 to 3 dimensions, but there was a significant (p-value = 
1.5e-40) decrease in the final AUC for the Grid algorithm for each higher dimension. This 
ultimately resulted in the Grid+Hyperprior algorithm performing at chance on the 
bipolar/pulse-width (4D) ground-truth models. In between these two extremes were the 
Random+Hyperprior and Evolution+Hyperprior algorithms that performed equivalently to 
EHVI+Hyperprior on the monopolar (2D) models, but performed increasingly worse on 
the bipolar (3D) and then bipolar/pulse width (4D) models, with the performance of 
Evolution+Hyperprior decreasing more as the dimension increased. Finally, while 
EHVI+Hyperprior had similar final AUCs for the monopolar (2D) and bipolar (3D) 
models, the error trajectory showed that it converged much more rapidly on the monopolar 
(2D) models, and that only after 60 samples did it obtain the same accuracy on the bipolar 





Figure 6.8: Search strategy performance across different dimension parameter 
spaces. 
(a) Same as in Figure 6.7. (b) Sample-wise AUC across all trials and subjects for models 
of a given dimension. Performance for EHVI+Hyperprior is shown when using the optimal 
configuration (Chapter 6, Section 3.3.3). 
6.3.3.3 EHVI and Hyperprior configuration parameters 
The overall behavior of the EHVI+Model and EHVI+Hyperprior algorithms could 
be further modified by adjusting two internal configuration parameters: 𝜅, which controlled 
the exploratory behavior of the algorithm, and 𝜆, which determined to what extent the 
hyperprior information was taken into account when fitting the surrogate model, and 
therefore was not relevant to EHVI+Model. For each of the subjects, the performance of 
the EHVI+Model algorithm was evaluated for different values of 𝜅, and the 
EHVI+Hyperprior evaluated for different values of 𝜅 and 𝜆. With EHVI+Model there was 
a clear improvement in both the final error and convergence rate for 𝜅 = 10, while 
performance was slightly worse for higher values, and significantly so for lower values (p-
value = 1.74e-46). (Figure 6.9a). There was also a larger variation in the AUC trajectory 




the EHVI+Hyperprior algorithm, varying 𝜅 had a similar effect as in EHVI+Model, (p-
value = 1.00e-23), while varying the hyperprior configuration parameter, 𝜆, did not 
significantly affect the overall results (p-value = 0.853, linear regression) (Figure 6.9c-d). 
 
Figure 6.9: Effect of EHVI configuration parameters on performance. 
(a) Final AUC and convergence for the EHVI+Model algorithm as the configuration 
parameter kappa is varied. (b) AUC trajectory for select values of 𝜅. (c) Surfaces shows 
the final AUC and convergence as both kappa and lambda is varied. (d) AUC trajectories 






6.3.3.4 Computation time  
Across the different models, the three algorithms that performed the best were 
EHVI+Hyperprior, EHVI+Model, and Random+Hyperprior. However, the first two had 
non-negligible computation times for each sample. With a limited time-window to perform 
the experiments during surgery, spending excess time to determine the next sample would 
reduce the total number of samples that could be collected. Therefore, the increased 
performance of a more sophisticated algorithm must offset any additional computational 
burden. By assuming a 25 minute (100 samples at 15 seconds per samples) window to 
perform the experiments and accounting for the three-second washout period between 
samples already built into the experimental protocol, we can recalibrate the algorithm 
performance within that limited time-frame (Figure 6.10). This recalibration had no 
notable effect on the algorithms when applied to the monopolar (2D) models. However, 
there was a significant decrease in the performance of the EHVI+Hyperprior algorithm for 
both the 3D bipolar (3D) (p-value = 0.0073) and bipolar/pulse width (4D) (p-value = 5.13e-





Figure 6.10: Wall-time comparison between EHVI+Hyperprior and Random+Model. 
(a) Final AUC for the top three algorithms when corrected to a maximum of 25 minutes 
wall-time. Error bars indicate 95% CI. Open boxes show the AU-ROC when all 100 
samples are included. (b) Sample wise AUC trajectory for all subjects and trials using the 
bipolar/pulse width (4D) models. X-axis has been scaled to reflect the computation time 
for the algorithms, rather than the number of samples. The gray bars for Time-Limited 
AUC in (a) correspond to the AUC trajectories over Time-Elapsed in (b). 
6.3.4 Effect of objective function characteristics on performance and behaviour 
Just as changes to the components and configuration parameters can affect the 
performance and behavior of an algorithm, so can the properties of the optimization 
problem it is trying to solve. Here we quantify how different properties of the optimization 
problem – subject-to-subject heterogeneity, and noise of the objective function – influence 






6.3.4.1 Variability between subject-models 
Comparing the final AUC and convergence between individual subjects, the 
general trends described in Chapter 6, Section 3.3.1. are preserved (Figure 6.11a). 
However, there is significant variability in final AUC and convergence between the 
subjects (p-value = 5.34e-72 and p-value = 7.47e-26, respectively; 5-way ANOVA) For 
the more sophisticated EHVI+Model and EHVI+Hyperprior algorithms the final AUCs are 
comparable, with EP010 trending lower than the other three (p-value = 9.09e-29). But, for 
the less complex Random, Evolution and Grid search strategies, the final AUC for Subjects 
3 and 4 are significantly lower than for Subjects 1 and 2, creating two groups of subjects 
with apparently ‘easy’ and ‘difficult’ objective functions. While the difference between the 
two groups is not clear for the EHVI+Hyperprior algorithm after 100 samples, the overall 
trajectory shows how the AUC increases much faster for the ‘easy’ subjects than for the 
‘difficult’ subjects (Figure 6.11b).  
 
Figure 6.11: Algorithm performance on individual bipolar (3D) subject models. 
(a) Final AUC and convergence after 100 samples for the four subjects with bipolar (3D) 
stimulation data. (b) Sample wise AUC trajectory for the EHVI+Hyperprior algorithm on 




6.3.4.2 Length scale  
To identify the differences between the ‘easy’ and ‘difficult’ objective functions 
we consider the length scale hyperparameters of the GP model fit to the subject data. As 
described in Chapter 6, Section 2.2.3 (Eq. 5), the length scale hyperparameters determine 
how much the output of the objective function can vary between adjacent inputs [26]. At 
lower length scales, the output can vary more, so we would expect a ‘wigglier’ objective 
function that may be more difficult to optimize. By comparing the length scales for the 4 
bipolar (3D) models to the final AUC across the different optimization algorithms, we 
found that final AUC was significantly correlated (Spearman, p-value < 0.05) with the 
length scales corresponding to the cathode and anode parameters of the cEP models, and 
the cathode parameter of the mEP models (Figure 6.12). This indicates that more complex 






Figure 6.12: Effect of length scale hyperparameters on performance. 
Each line shows the final AUC for each algorithm across each subject as a function of the 
length scale hyperparameters. (a) Length scales of GP model fit to cEP data. (b) Bipolar 
surfaces for the subjects with the lowest and highest length scales for the cathode and anode 
parameters. The surfaces within the plot represent the cross-sections at 1, 3, and 5 mA 
stimulation amplitude. 
6.3.4.3 Measurement noise  
Lastly, measurement noise can vary between different subjects, recording 
equipment, and changes to the biomarker, so it is valuable to know the tolerance of an 




artificially scaled to produce objectives with more and less measurement noise, and the 
performance of the four search strategies was evaluated (Figure 6.13a). As the CNR 
decreases, the performance of the optimization algorithm monotonically decreases and the 
variability of the AUC increases. These curves show that most algorithms can tolerate an 
2x decrease in CNR without much degradation in performance, and can perform better than 
chance (AUC = 0.50) at up to a 10x decrease in CNR. 
 
Figure 6.13: Effect of noise on performance. 
(a) Each line represents the final AUC for a given algorithm as the measurement noise of 
the objective function is altered. (b) Per-sample trajectory of the AUC for the 
EHVI+Hyperprior algorithm on a subset of objectives with different measurement noise. 
Error bars and patches indicate the standard error. 
6.3.4.4 Optimizing bipolar/pulse width (4D) parameter space for 500 samples 
Given the limited time available to perform these experiments in the OR, most of 
our analysis was limited to 100 samples or fewer. In the case of the bipolar/pulse width 
(4D) model, this resulted in no algorithm achieving a final AUC greater than 0.7. To better 
characterize the performance and behavior of these algorithms, we performed an additional 




samples, the model-based Random and EHVI search strategies achieved a final AUC 
greater than 0.8. This shows that these algorithms can scale to higher dimensions, but will 
need additional samples to achieve performance comparable to the bipolar (3D) models. 
 
Figure 6.14: Performance for optimization trials with 500 samples. 
(a) Final AUC and convergence after 500 samples for the four subjects with bipolar/pulse 
width (4D) stimulation data. (b) Sample wise AUC trajectory for each search strategy with 
Hyperprior algorithm on individual subjects. Error bars (a) and patches (b) indicate 95% 
confidence interval. 
6.4 Discussion 
We used electrophysiology data (cEP and mEP) recorded from patients with PD 
undergoing STN DBS surgery to create a platform for evaluating performance of multi-
objective optimization algorithms designed to reduce the size of the stimulation parameter 
space by estimating the Pareto ranking. While data-driven optimization approaches have 
been proposed for designing or adjusting stimulation settings for neural modulation, this is 
the first time that multi-objective data-driven optimization (maximizing cEP and 
minimizing mEP) has been applied to direct electrophysiological biomarkers in a clinical 




purpose was a sample-efficient Bayesian optimization approach with the EHVI acquisition 
function. Critical algorithm components included the use of a surrogate model, and a well-
configured acquisition function. We demonstrated that application of our optimized 
algorithm reduced the parameter space available to the clinician by at least a third, although 
this study was not designed to validate the use of biomarkers for clinical programming. 
This study followed a framework for designing multi-objective data-driven optimization 
solutions that can be applied across DBS applications and electrode designs [37]. 
6.4.1 Biomarkers for optimizing DBS 
The search for DBS biomarkers that can serve as a surrogate to clinical observation 
is an active area of research. In this study we used cEP and mEP to highlight the importance 
of multi-objective optimization (maximizing benefit, minimizing side effects). The most 
well-studied biomarker in PD is subthalamic beta power, which has been investigated as a 
signal for responsive control [72], [74] of stimulation parameters in NHP models of PD, 
and in small studies of responsive stimulation in humans [71], [75]. Cortical gamma power 
has been proposed as a biomarker of dyskinesias (a side effect) [17]. Non-
electrophysiologic biomarkers of DBS efficacy include kinematic measurements [27], 
which can serve as a surrogate for tremor severity, and thereby used as an objective 
function for closed-loop optimization techniques in patients with PD or essential tremor 
[88], [89].  
Beyond PD and movement disorders, a recent study in DBS for epilepsy found that 




hippocampus, that the ability to elicit hippocampal EPs through ANT stimulation was 
correlated with a decrease in seizure frequency [90]. As they become better understood, 
each of these biomarkers can be incorporated as an objective for a single- or multi-objective 
optimization system. 
6.4.2 Prototyping data-driven multi-objective optimization  
By using the cEP and mEP data in combination with the previously reported 
framework [37] for designing data-driven optimization systems, newly extended for multi-
objective optimization problems, we were able to evaluate how 10 different algorithms 
performed on three different parameter spaces across five subjects (one subject had only 
monopolar (2D) parameter space). From the component test, it was clear that the most 
important feature for this optimization problem was the use of a surrogate model. Without 
using a surrogate model to interpolate across the entire parameter space, the Pareto ranking 
could only be calculated for the stimulation settings that were actually tested by the 
algorithm. While this approach may work when many samples can be collected relatively 
quickly it does not work well with the limited data that can be collected during this 
particular experiment. In contrast, when using a surrogate model to interpolate the effect 
of untested stimulation settings on cEP and mEP, the Pareto ranking could be estimated 
across the entire parameter space. Moreover, the surrogate GP models allowed the 
noiseless measurements of cEP and mEP to be estimated. 
Second in importance was the use of the EHVI acquisition function, especially on 




function, this is an active field of research and it is certain that even more effective 
acquisition functions can be integrated with this system [91]–[93]. Hyperpriors also did 
offer some benefit, but this was offset by the increased time necessary to calculate the next 
sample. However, this can be addressed with high-performance computing hardware and 
software-level changes. Moreover, this does not diminish the potential utility of alternative 
optimization approaches where data from previous subjects are used to inform the 
surrogate model fitting or search algorithm.  
The behavior of the optimization algorithm is inexorably connected to the 
characteristics of the optimization problem. One of the key characteristics of the objective 
function is the dimensionality of the parameter space. As we compared the same algorithms 
across parameter spaces of increasing size/dimension, we found that they all suffered a 
decrease in performance. However, the performance of the algorithms deteriorated at 
different rates. In the case of the Grid algorithm, even when using a surrogate model, it was 
unable to perform better than chance on the bipolar/pulse width (4D) parameter space. 
When the simulations were allowed to run for 500 samples on the bipolar/pulse width (4D) 
models (6.3.4.4), the Grid algorithm still performed below chance. However, after 50 
samples the EHVI+Hyperprior and Random+Hyperprior algorithms achieved AUCs on the 
bipolar/pulse width 4D parameter space comparable to the bipolar (3D) parameter space. 
While these methods can be directly extended to more complex electrodes with higher-
dimensional parameter spaces, these findings show that it will take a combination of the 
right algorithm, and more efficient data collection to solve these more difficult optimization 




6.4.3 Related and future work 
Data-driven optimization approaches have been gaining traction as an effective tool 
for designing and optimizing stimulation settings for neural modulation. Recent 
approaches have used multi-objective particle swarm optimization to identify stimulation 
settings that selectively activated fiber tracts in subject-specific biophysical/finite-element 
models [94], and a genetic algorithm to optimize a thalamocortical basal ganglia model-
based proxy of stimulation effectiveness [29]. While powerful, these approaches rely on 
complex models that are time-consuming to construct, and evolutionary optimization 
algorithms that can often require >10,000 samples to converge, limiting them to offline 
use. An alternative approach that could be applied online used a single-objective Bayesian 
optimization algorithm to tune a controller for regulating STN beta power in a mean-field 
model of PD [65]. Beyond DBS, data-driven optimization has also been applied for spinal 
cord stimulation [95]. In the approach presented here, we leveraged a sample-efficient 
Bayesian optimization approach to solve a difficult multi-objective optimization problem 
based on electrophysiological biomarkers that can measured in real-time. Taken together, 
this will pave the way for subject-specific online optimization of multiple objectives in 
vivo.  
While the EHVI+Hyperprior Bayesian optimization algorithm outperformed all 
others in this study, it will still be necessary to validate in vivo. However, there are several 
additional engineering hurdles that need to be overcome, including automated real-time 
calculation of the cEP and mEP features. If a Random or Grid search strategy had 




analysis showed improved performance with a Bayesian optimization approach that relies 
on real-time measurements, these efforts are justified. Additionally, as 8-contact 
segmented leads are becoming standard, the surrogate models will need to be adapted to 
this more complex parameter space. The parameter space of bipolar contact configurations 
on a segmented lead can reasonably be represented in four dimensions by using x-y 
coordinates as parameters for the cathode and anode, plus parameters for amplitude and 
pulse width. The GP models used by the Bayesian optimization algorithm here could be 
readily applied to such a 6D parameter space. However, if stimulation settings were to 
become complex enough that ten or more dimensions were needed to define the parameter 
space, other models specifically designed for high-dimensional Bayesian optimization 
should be considered [67].  
In parallel to the implementation of this data-driven optimization approach in vivo, 
there are several natural extensions to the algorithm itself. One such extension is the 
inclusion of energy consumption as an objective to minimize. This can be valuable, as 
many DBS devices require an outpatient surgery to replace the battery and patients with 
rechargeable devices would still benefit from an increased battery life [96]. Another option 
is to incorporate optimization with learnable safety constraints [58]. These algorithms are 
designed to avoid regions of the parameter space that could be dangerous. While 
stimulations that create unwanted mEP responses are not dangerous per se, avoiding these 
stimulation settings could further refine the parameter space to improve efficiency and 
provide a more comfortable experience for patients. Finally, state-dependent optimization 




state – for example, as medication levels change. As each of these approaches introduce 
additional complexity to the optimization problem, it will still be necessary to properly 
design the algorithms by following a framework such as described here.   
6.4.4 Limitations  
The conclusions drawn from this study should be limited to the performance and 
behavior of the data-driven optimization algorithms, and not the clinical implications of 
the stimulation settings or the biomarkers, as they have not been validated. Additionally, 
the datasets for some subjects were incomplete, which required us to augment the dataset 
with additional points to provide robust ground-truth models for simulation experiments. 
While the augmented data were based on experimental findings that were consistent across 
patients (e.g. EP amplitude sigmoidally increasing with increasing pulse width), it still 
likely resulted in ground-truth models less consistent with the original subjects. However, 
the overall characteristics of the models still allowed for evaluation of the algorithms. 
Additionally, with the data available, we could not compare clinical settings with the 
calculated Pareto ranking for all patients. But this was not the focus of the current study 
and only served as a demonstration of the potential utility of a multi-objective approach. A 
prospective study would be necessary to evaluate performance of optimization algorithm 
and putative biomarkers for clinical programming. Finally, our ground-truth models 
assumed that the biomarker response to stimulation was stationary – i.e. the effect of brief 
stimulation does not change over time. Given that cEP and mEP quantify direct activation 
of relevant neural pathways, and the consistent repeated stimulation results in Chapter 6, 




While the ultimate goal in DBS programming is to find the single stimulation 
setting that best treats the patient, our multi-objective approach produces a reduced set of 
potential settings. Even though electrophysiological biomarkers, such as cEP and mEP, 
maybe be quantitative and more objective, they cannot account for all aspects of the therapy 
and some degree of clinical testing will be necessary. This approach would allow that 
clinical testing to focus on stimulation settings with a higher likelihood of being effective. 
6.4.5 Conclusion 
Data-driven multi-objective optimization approaches have the potential to improve 
DBS programming and provide patients with more precise and effective therapies. 
However, these optimization algorithms need to be carefully designed, as the wrong 
choices can lead to chance-level performance, or take too long to compute, therefore not 
saving time in the long run. We describe a framework based on Bayesian optimization that 
is well suited to this problem. Future studies are needed to test the utility of optimization 
algorithms in real-time and assess their performance with alternative biomarkers or 
objective functions.  
6.5 Supplement 
6.5.1 Estimating measurement noise 
To provide a better estimate of the sample-to-sample measurement noise, data from an 
additional Subject 6 was collected where some stimulation settings were applied twice. 




Abbott 6172 clinical electrode twice during the data collection experiment. These repeated 
stimulation settings and cEP were fit to a model as described in Chapter 6, Section 2.2 
(Figure 6.15a), and the contrast to noise ratio (CNR) was calculated. The noise in the 
simulation models for subjects 1-4 was then calibrated to that CNR.  
 Repeated stimulation using identical settings produced consistent cEP responses, 
with a CNR of 8.2. Additionally, no trend was observed when comparing the first 
stimulation to the second stimulation using the same setting (Figure 6.15d). This indicates 
that the order and timing of stimulation does not influence the effect of the stimulation on 
cEP. 
 
Figure 6.15: Repeated stimulation in a segmented electrode to estimate measurement 
noise. 
(a) Spatial layout of the monopolar parameter space for a segmented electrode. Each 
colored circle corresponds to a stimulation setting (b) GP model fit to the repeated 
stimulation settings. The surface is the expectation of the GP model. (c) Top down view of 
the GP model. (d) Comparison between the first and second applications of the same 





CHAPTER 7. CONCLUSION 
This dissertation presented a framework for designing data-driven optimization 
systems for neural modulation. This framework was developed using a medial septum 
optogenetic stimulation model with the objective of maximizing hippocampal gamma, the 
power of the oscillations between 33 and 50 Hz measured from the hippocampus. The 
framework was then extended to a number of other neural modulation applications 
including, optimizing to a setpoint, state-dependent optimization, optimization with 
learnable safety constraints, and optimization with multiple objectives. This dissertation 
covers these extensions through different components of the framework, but efforts are 
ongoing to build upon these results (Figure 7.1). 
 
Figure 7.1 Status of each project based on the framework. 
Filled bars indicate each step of the framework covered in this dissertation for each project. 






The following sections contextualizes the different projects in terms of the practical 
considerations when applying the framework, and role and utility of the framework for 
engineering, scientific, and clinical perspectives. 
7.1 Implementing the framework in practice 
7.1.1 Data collection 
The first step to implement this framework is the collection of data from an initial 
cohort of subjects. Since the goal is to use the data from subjects 1 through N to design an 
effective algorithm for some future, unknown subject N+1, it is important that samples 
collected are representative of the entire parameter space. The approaches for collecting 
the data can be loosely categorized as non-active and active.  
7.1.1.1 Non-active data collection 
 Non-active data collection includes approaches where the set of stimulation settings 
to be evaluated can be defined in advance. The simplest approach is a grid search where a 
limited number of values are selected for each parameter and all combinations are 
evaluated. For example, in a 2-dimensional parameter space of amplitude and frequency 
bounded on 0-4 mA and 20-200 Hz, respectively, with 2 values for each, a possible set of 
stimulation settings could be [1 mA, 20 Hz], [3 mA, 20 Hz], [1 mA, 130 Hz], and [3 mA, 
130 Hz]. This is the approach used for data collection in the rat optogenetic medial septum 
studies and the human STN DBS experiments. While adequate for parameter spaces with 




An alternative to the grid search is a uniform random search [97]. In this approach, 
stimulation settings are selected by drawing a random value for each parameter from 
independent uniform distributions. Using the same parameter space defined in the grid 
search example, a possible set of stimulation settings could be [3.8 mA, 84 Hz], [1.9 mA, 
183 Hz], [3.2 mA, 158 Hz], and [0.8 mA, 22 Hz]. The advantage of this approach is that it 
evaluates 4 different values for amplitude and 4 different values for frequency, compared 
to just 2 each for the grid search. While still useful for building regression models, one 
limitation of a uniform random search is that the data is not amenable to classical statistical 
tests like analysis of variance. Regardless, a uniform random search can be an effective 
approach for many of the parameter spaces possible with commonly used neural 
modulation technologies. 
7.1.1.2 Active data collection 
 While effective at lower dimensions, the grid and random search strategies do not 
scale to the higher dimensional parameter spaces becoming possible with new 
developments in neural modulation technology with many additional parameters and 
settings to optimize. As such, more sophisticated approaches will be needed for collecting 
the data needed in this design framework. One natural approach is active learning. Whereas 
the goal of an optimization algorithm is to identify a global maximum of an objective 
function by avoiding suboptimal regions of the parameter space, the goal of an active 
learning algorithm is to learn the objective function across the entire parameter space. In 




approach used in this framework can be framed as active learning by using an acquisition 
function to minimize uncertainty, but not to optimize [36].  
 Another situation that could potentially require active data collection would be in a 
clinical context, where it may not be ethical to intentionally submit subjects to suboptimal 
stimulation settings. In such a case, an optimization approach combining a high level of 
exploration along with learnable safety constraints could be used to carefully explore the 
parameter space within a therapeutically reasonable window. While not motivated by 
clinical constraints, much of the data used to design the safe optimization algorithm in 
Chapter 5, was collected during previous optimization experiments, but was still useful 
within the design framework. 
7.1.2 Modelling 
The modeling step is where the data collected from an initial cohort of subjects is 
used to construct simulation models that can act as proxies for the actual subjects. The key 
advantage of the data-driven optimization approach is the minimal number of assumptions 
needed for building the simulation models. Rather than modeling the underlying 
biophysical mechanisms of stimulation and the brain, statistical models can be used to 
directly model the data. Since a data-driven optimization algorithm is not concerned with 






7.1.2.1 Model structure 
 When selecting the model structure, it is important that it matches the 
characteristics of the response across the parameter space. Particular considerations 
include, the linearity of the response and the presence of discontinuities, along with the 
distribution and heteroscedasticity of the noise. In the simplest case, a polynomial with 
Gaussian noise may suffice. However, nonlinear models with more esoteric noise 
distributions may be required. In all of the examples shown here, the data was modeled 
using a Gaussian process regression model. This non-parametric approach was sufficient 
for capturing the relatively smooth changes in the response to stimulation across the 
parameter space and was able to naturally estimate the distribution of the noise. In practice, 
for neural modulation problems with fewer than 10 dimensions and no sharp 
discontinuities, Gaussian process regression models with squared exponential or Matérn 
covariance functions are a reasonable first approach. 
However, GPs do not scale well with large amounts of data (>1000 observations) 
or to higher dimensions (>10), as inference will take an extremely long time, decreasing 
the throughput for testing different data-driven optimization algorithms and configurations. 
In these situations, model structures such as random forests or neural networks might be 
more appropriate. 
7.1.2.2 Data augmentation 
 Another aspect of constructing the models is data augmentation. While the ideal 




entire relevant region of the parameter space, this may not always be possible. For example, 
if the initial data was collected as part of a different study, regions of the parameter space 
may not have been extensively sampled, but may be relevant for the purpose of the 
optimization problem. In this case, the data set can be augmented with additional data 
points based on prior knowledge or assumptions to construct a more physiologically 
realistic model. In Chapter 5, when constructing models mapping stimulation amplitude to 
performance on a memory task, additional data points with poor performance were added 
at higher voltages to create an unsafe region of the parameter space without the need to 
expose the subjects to unsafe stimulation settings. In Chapter 6, not all combinations of the 
4 stimulation parameters were tested in all subjects due to limited time available to collect 
data during the surgery to implant the DBS device. In this case, the augmenting data was 
estimated based on the other subjects and other experiments. While the resultant simulation 
models were likely less accurate proxies of the original subjects, the overall characteristics, 
such as noise and complexity, made them sufficient for prototyping and benchmarking 
different data-driven optimization approaches.  
7.1.2.3 Subject characteristics 
 A final consideration when deciding the model structure is what other information 
can be interpreted from the relationship between the characteristics of a given model and 
the performance of different algorithms. A metric that can applied to essentially any model 
is the CNR. Borrowed from image processing, this metric was significantly correlated with 
the performance of the optimization algorithms in Chapter 2, Section 5.5 and Chapter 6, 




problem. In Chapter 5, the behavioral objective in the memory optimization experiments 
had a CNR below 1.0 for some subjects. This explains some of the challenge of that 
optimization problem, despite only optimizing a single parameter. In contrast, the evoked 
potential objectives in Chapter 6 had a CNR above 8.0, which allowed for optimization of 
a 4 dimensional parameter space using a more complex multi-objective optimization 
approach.  
 Another characteristic of the objective function that can be interpreted from the 
Gaussian process models used in this dissertation are the length scales. The Gaussian 
process covariance functions with automatic relevance determination fit a length scale 
hyperparameter to each dimension/parameter of the parameter space that controls how 
much the output can change between two adjacent stimulation settings. In Chapter 6, 
optimization algorithms performed worse in the subjects with the smaller length scales. In 
this case the relative complexity of the different subjects could be readily observed. 
However, with additional subjects or higher dimensional parameter spaces, a quantitative 
measure will be useful for assessing the difficulty of the optimization problem, measuring 
the relevance of each dimension/parameter, and for identifying clusters of similar patients. 
7.1.3 Prototyping 
After the construction of the simulation models that can serve as high-throughput 
proxies for the original subjects, the next step of the framework is to use these simulation 





7.1.3.1 Selection of algorithms and configurations 
In Chapter 2, Bayesian optimization, a surrogate model algorithm, outperformed 
the gradient approximation and evolutionary algorithms. This was generally expected 
based on the characteristics of the optimization problems – smooth, noisy, expensive – but 
it was important to verify this empirically. However, Bayesian optimization is not suitable 
for every problem. In Chapter 2, Section 5.5, the UCB(0.4) algorithm that performed well 
on the optogenetic optimization problem regularly failed to find the optimum on the rare-
event Easom benchmark objective function. In objectives with rare or many local extrema, 
discontinuities, or high-dimensional parameter spaces, an evolutionary algorithm may have 
better performance. Ultimately, these characteristics are determined through the data 
collection and modeling steps of the framework, and the appropriate algorithm is 
determined empirically through prototyping. 
 Another consideration in the selection of algorithms is the execution or update time. 
This is the amount of time the algorithm needs to propose a new set of stimulation settings 
after receiving the output from the previous iteration. This was not an issue in the single 
objective optimization problems as the update time was generally less than a second, and 
iterations of the algorithm was seconds to days apart. However, in Chapter 6, some of the 
multi-objective optimization approaches took a considerable amount of time to update, 
such that it impacted the overall performance of the algorithm given the limited time with 
which data can be collected. This issue may be addressed through the use of additional 




7.1.3.2 Design criteria 
In conjunction with selecting the algorithms to prototype, the performance metrics 
to evaluate them must be specified. The primary design criterium for almost any single 
objective optimization problem is the error between the output of the underlying objective 
function at the estimated optimal and the ground-truth optimum. However, in the case of 
multiple objectives, the output of the optimization algorithm is a Pareto set of stimulation 
settings. As a result, measuring the error between the estimated optimum and the ground-
truth solution is less straightforward. In Chapter 6, the output of the multi-objective 
algorithm was framed as a classification of whether a stimulation setting was within the 
Pareto set or not. While this worked for the goal of reducing the overall size of the 
parameter space, other metrics may be more appropriate depending on the specific goals 
of the optimization problem. 
In addition to the overall accuracy of the estimated optimal, there are other 
secondary criteria that can be used to assess the performance of the algorithm. For any 
measure of error, the convergence rate can be calculated. However, it should be noted that 
convergence rate describes how quickly the algorithm arrived at a solution, not necessarily 
the accuracy of the solution. An alternative approach to combine error and convergence 
rate is the sum of the error over the entire optimization trajectory [98]. While error and 
convergence rate can serve as general purpose performance criteria, other optimization 
problems may require specific solutions. For example, when designing the optimization 
algorithm with learnable safety constraints in Chapter 5, the maximum overshoot of the 




performance metric to evaluate safety of the different algorithm configurations. Similarly, 
in Chapter 6, the computation time to select the next sample to evaluate was also considered 
as part of the design criteria. 
7.1.4 In vivo validation 
7.1.4.1 Verifying assumptions 
The key purpose of in vivo validation is verifying the assumptions made during 
modeling. For example, in all of the examples shown in this dissertation, it was assumed 
there was no interaction between the effects of stimulation. Consequently, in most of the 
examples, the data collection procedure randomized between different stimulation settings. 
However, during optimization, an algorithm can apply the same or similar stimulation 
settings sequentially. It is possible that interaction between sequential stimulation settings 
may have been obscured when randomizing between stimulation, but a confound when 
optimizing in vivo. If detected, this could have been addressed by increasing the time 
between stimulation when practical, or by using an alternative optimization approach that 
takes into account the history of stimulation settings evaluated. 
7.1.4.2  Algorithm refinement 
 The other benefit of validating the optimization algorithm in vivo is the collection 
of additional data that can be used to further refine the algorithm. In terms of parameter 
space coverage, using data collected with uniform random search or an active learning 




experiments was useful in Chapter 5. Moreover, data collected during optimization could 
identify any interactions between subsequent stimulation settings as described in the 
previous section. 
7.2 The framework in perspective 
7.2.1 Engineering perspectives 
 The overall approach of this framework is fairly standard in more established fields 
of engineering such as electrical and aerospace. For example, autopilot controls can be 
designed by evaluating different candidate control algorithms in simulation before 
validating them in realistic conditions [99]. However, the simulations used in these fields 
of engineering are based on well-understood physical laws that can be accurately modeled 
to an arbitrary resolution. In contrast, the biophysical models used in neuroscience are of 
varying resolutions and limited accuracy. This is particularly the case for models of brain 
stimulation, and may result in challenges when translating the optimization approaches 
designed in silico. Rather than building simulation models from biophysical first 
principles, the framework described here circumvents these issues by using statistical, data-
driven simulation models. While potentially requiring upfront costs to collect the initial 
data set, the resultant optimization algorithms perform as predicted, and efficient solutions 
were designed for a range of different neural modulation problems. Of course, a limitation 
of using a statistical model to interpolate between collected data points is that the resultant 





7.2.1.1 A tool for interpreting optimization performance  
 A key advantage of using a simulation based design framework such as the one 
described here, is the ability to anticipate results and diagnose failures. This was valuable 
when identifying the optimal stimulation setting that modulated hippocampal gamma 
power to a setpoint in Chapter 3. Prior to modeling the collected data, applying the setpoint 
transformation and performing the simulations, it was not apparent that the solution to the 
optimization problem would be a set of equivalent stimulation settings forming a ridge 
across the parameter space. Knowing this helped explain the behavior of the search 
trajectory as the estimated optimal stimulation setting would alternate between distant 
regions of the parameter space. Similarly, the simulations in this framework helped 
highlight the importance of selecting the correct algorithm configurations. When 
maximizing hippocampal gamma power in Chapter 2, the simulation framework accurately 
predicted and explained the difference in performance between the UCB(0.4) and 
UCB(0.01) versions of the Bayesian optimization algorithm. Ultimately, this design 
framework can serve as a valuable tool for predicting and understanding the behavior of a 
data-driven optimization algorithm when deployed in practice.  
7.2.1.2 Relationship to control and reinforcement learning 
Optimization is just one part of the broader engineering toolbox that can be used 
for delivering effective brain stimulation interventions. In particular, optimal control and 
reinforcement learning are potential approaches for learning a policy to determine 




system. While the majority of the applications in this dissertation assumed that the 
objective function was static, in Chapter 4 when medial septum optogenetic stimulation 
was applied at varying depths of anesthesia, it was shown that the effect of stimulation was 
influenced by anesthetic level. To address this, the pre-stimulation state was measured and 
added as a predictor for the surrogate Gaussian process model used in Bayesian 
optimization, and the predictions were conditioned on this state. While this approach was 
effective and a natural extension of the previously developed optimization tools, controls 
and RL based approaches could readily be used, and have seen some applications in neural 
modulation [100], [101]. However, these approaches, while powerful, still need to be 
designed and can be even more complex than a static optimization approach, similarly 
benefitting from a design framework based on statistical models derived from subject data 
[102]. 
7.2.2 Basic science perspectives 
7.2.2.1 Tighter control of neural modulation experiments 
Neural modulation has become a valuable tool to study functional properties of neural 
circuits and how brain activity relates to behavior. However, it can be important to account 
for subject variability and state-dependent effects of stimulation when conducting 
experiments using neural modulation. For example, in Chapter 3, Section 3.3.1, the medial 
septum optogenetic stimulation settings needed to modulate hippocampal gamma power to 
a given set point varied from between subjects. Similarly, in Chapter 4, the effect of medial 




underlying state of the brain – in that case, depth of anesthesia. This has also been seen in 
relation to locomotive activity of rats undergoing medial septum optogenetic stimulation 
[103]. Correct application of max/minimization, setpoint, and state-dependent optimization 
has the potential to more accurately modulate neural state. Integrating these approaches is 
ultimately a stepping stone towards more sophisticated optimal control approaches that 
may be applicable to more challenging neural modulation problem. 
7.2.2.2 Automated design of optimization solutions 
Another key consideration is the accessibility of optimization as a tool. Like with any 
tool, experimenters would want an effective and reliable optimization solution as “off-the-
shelf” as possible, avoiding the need to manually design and compare different 
configurations. There are several approaches to designing a bespoke optimization solution. 
The simplest is automatic benchmarking against a fixed battery of algorithms. This was the 
approach used in the applications of this framework. Specifically, a fixed grid  of algorithm 
configurations was evaluated, except for in Chapter 5, where a uniform random search was 
used to determine which algorithm configurations to prototype in simulation.  
This can be further built-upon by directly optimizing the configuration of the 
optimization algorithm. From the perspective of the design framework, the input space 
would be the algorithm configuration and the output objective would be the performance 
of the configuration on a set of simulation models. This approach may become necessary 
as optimization algorithms and neural modulation problems become more complex, and 




concept of ‘optimizing the optimizer’ has extended to training recurrent neural networks 
as general purpose solvers for sequential sampling optimization problems [98]. This more 
general approach may lead the way for optimization solutions for neural modulation that 
can perform well off-the-self in a variety of applications. 
7.2.3 Clinical perspectives 
7.2.3.1 Integration with clinical practice 
 While the technology for data-driven optimization is well-established in other fields 
and shows promise for neural modulation, one of the last hurdles will be integrating the 
algorithms with clinical practice. Given the already busy clinical schedule for treating DBS 
patients, it will be critical to integrate optimization solutions within the existing workflow. 
In the multi-objective approach detailed in Chapter 6, the optimization would take place 
during the procedure to implant the clinical device. However, this approach does 
temporarily interrupt the surgery and so additional considerations are necessary to 
minimize the optimization time or to develop alternative biomarkers that can be measured 
outside of the operating room. 
 A recent approach used an accelerometer in real-time to detect tremor-related 
symptoms while automatically adjusting stimulation under the supervision of a clinician 
[27]. This has the advantage of replacing an existing component of the clinical workflow 
with an automated process. However, some symptoms and side effects such as freezing of 
gait or dysarthria may be more difficult to automatically measure and detect. An alternative 




observations of the clinician to suggest stimulation settings to guide the programming 
process interactively. A proof-of-concept software application is available at: 
https://github.com/Precision-Neurodynamics/optimization_assistant.  
7.3 Final remarks 
The focus of this work was designing data-driven optimization algorithms for real-
time use based on statistical models fit to subject data. However, there is a growing body 
of work using complex biophysical models to optimize stimulation parameters and 
policies, and even to identify novel types of stimulation paradigms [29], [65], [94]. While 
both of these approaches work towards the same goal of better delivering neural 
modulation, they are not mutually exclusive and can serve to complement each other. The 
offline approaches can be useful for a priori identifying regions of the parameter space 
with a high likelihood of producing the desired effect, while the online approaches can 
further refine the parameter space based on direct interaction with the subject. Continued 
development of both approaches will be critical to improving neural modulation as a 
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